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INTRODUCTION
Oral cancer has a worldwide incidence of 300,400 cases and is 
responsible for 145,400 deaths annually [1]. Oral cancer has a 
5-year survival rate of 50%–60% [2]. The distribution of oral 
cancer is approximately 32% in the buccal mucosa, 22% in 
tongue, 11% in lower lip, 11% in palate, 8% in vestibule, 5% in 
alveolus, 5% in floor of the mouth (FOM), and 3% in the gingi-
va [3]. Due to the heterogeneous nature of oral cancer, the func-
tional and cosmetic results, and the coexistence of frequent 
medical comorbidities, treatment options should be evaluated 
through the multidisciplinary team and evaluated before reach-
ing the final plan. In many countries, surgery remains the first 
option of treatment for oral cancer [2]. 
The effects of oral cancer surgery can have a serious impact 
on a patient’s quality of life and can impair appearance and 
functional characteristics such as speech, mastication, and swal-
lowing [4]. Therefore, these guidelines focus on oral cancer sur-
gical treatment under the assumption that surgery is a chosen 
treatment after a multidisciplinary discussion under any circum-
stances. The Korean Society of Otorhinolaryngology-Head and 
Neck Surgery released guidelines for the standard management 
of oral cancer in 2011 and the Korean Society of Thyroid-Head 
and Neck Surgery (KSTHNS) published treatment guidelines for 
patients with laryngeal cancer in 2017 [5]. There have been 
many advances in oral cancer diagnosis and treatment over the 
past decades, but clinical debate exists in many areas. These 
guidelines summarize advances in the surgical management of 
oral cancer, including preoperative diagnostic techniques and 
postoperative management. 
Target population
These guidelines apply to clinicians, patients, researchers, and 
health policy makers involved in diagnosis and treatment of oral 
cancer patients. These recommendations focus on diagnosis and 
work up, prevention, surgical treatment, postoperative care, and 
salvage surgery of oral cancer. Separate recommendations for 
initial surgical treatment are given for each subsite such as the 
oral tongue, maxillary gingiva and hard palate, mandibular gin-
giva, FOM, buccal mucosa, and the retromolar trigone (RMT). 
Intended users
These guidelines are primarily for head and neck surgeons to 
treat oral cancer patients. These guidelines are comprehensive 
updates to the current surgical treatment methods for patients 
with oral cancer. All patients should have access to full support 
services and oral cancer care professionals for optimal treatment 
and follow-up. These guidelines provide general depth in the as-
sessment and surgery of oral cancer and are intended for use by 
clinicians working in multidisciplinary team settings, including 
medical and radiation oncologists, plastic and reconstructive sur-
geons, specialized nurses, dentists, physical medicine and reha-
bilitation workers, speech and swallowing therapists, and coun-
selors who provide patient support.
MATERIALS AND METHODS
Organization of the committee
The KSTHNS’s guideline committee developed the clinical rec-
ommendations. Task Force Chairman (KHL) has been appointed 
by the PSTHNS President (PSJ) with the approval of the com-
mittee. A task force consisting of 31 experts with complementa-
ry expertise was appointed. The guideline committee had com-
plete editorial independence from the KSTHNS. The clinical 
guideline committee participated in a conference call to review 
and evaluate the development of various recommendations and 
guidelines at regularly scheduled face-to-face meetings. 
Literature search and quality assessment
This literature search was performed on November 12, 2017. A 
literature search was conducted with the support of four databas-
es including MEDLINE, EMBASE, Cochrane Library, and Kore-
aMed. The search string used was: (oral OR mouth/exp OR mouth 
OR oris) OR (tongue* or gloss* or lingua*) OR (“mouth floor” 
or “floor of mouth” or sublingua* or “mouth floors” or “floors 
of mouth) OR (gingiva* or gum* or “interdental papilla” or “al-
veolar process” or “alveolar processes” or “ alveolar ridge”) OR 
(“hard palate” or “hard palates” or “palatine bone”) OR (“buc-
cal mucosa” or “mouth mucosa” or “oral mucosa” or bucca* or 
“buccal mucosal” or “mouth mucosal” or “oral mucosal”) OR 
(retromola*) OR (neoplasms or cancer or carcinoma or malignant 
or malignancy or tumor or tumour). During the search, we ap-
plied the following limits: search fields: Title, Abstract, Key-words; 
publication type: article, review, article in press; species: humans. 
In order to obtain an adequate number of papers, the search was 
not limited by publication year. After reviewing the title, unrelated 
documents were excluded. The remaining selected documents 
were independently reviewed by two committee members who 
decided whether to exclude or include the documents. Key ques-
tions selected, the number of documents retrieved, and keywords 
used in the search results are shown in Supplementary Table 1.
   The Korean Society of  Thyroid-Head and Neck Surgery (KSTHNS) 
developed the practice guideline about surgical treatment of 
oral cancer.
   These guidelines provide suitable treatment options following 
subsites of oral cavity and suggest proper reconstruction meth-
ods with considering defect site. 
   Authors summarizes advances in the surgical management of 
oral cancer, including preoperative diagnostic methods and 
postoperative management. 
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Qualification of literature and evidence levels, and grades of 
recommendations
Quality of evidence for use in these guidelines was evaluated by 
the American College of Physicians (ACP) guideline grading sys-
tem, as related to critical appraisal and recommendations on ther-
apeutic interventions (Table 1). The review of evidence under ACP 
guidance provides information on whether the studies included 
in the evidence review are reliable and accurate, and provides a 
reasonable assessment of potential adverse events. RoBANS (Risk 
of Bias Assessment Tool for Nonrandomized Study) was used to 
test non-critical control (non-randomized controlled trials [RCTs]) 
and to assess the quality of observational studies, and AMSTAR 
(A Measurement Tool to Assess the Methodological Quality of 
Systematic Reviews) was used for systematic review and meta-
analysis evaluation [6,7]. Similar to our committee’s previous 
guidelines, evidence levels were classified as high-quality, mod-
erate-quality, or low-quality evidence (Table 2) [5]. This system 
provides the highest level of RCT, the lowest level of case series 
or expert opinion. The hierarchies rank studies according to the 
probability of bias. RCTs are placed at the highest level because 
they are not biased and have a low risk of systematic errors. The 
case series or expert opinion is often biased by the author’s ex-
perience or opinion and cannot control the confounding factor. 
Evidence may be inconsistent, poor or insufficient, and thus can-
not determine the balance of benefits and risks. Lack of evidence 
has resulted in a “no recommendation” decision. No recommen-
dation does not mean that the committee opposes the action, 
only that it cannot decide for or against the matter.
A Delphi method was used to establish consensus. Head and 
neck surgeons with more than 10 years of experience were in-
vited to participate as part of the panel of experts. In the first 
round, 67 best practice rec-ommendations were distributed to 
the panel. The panel members were asked to provide comments 
on each recommendation with “fully agree,” “agree,” “neither 
agree nor disagree,” “disagree,” or “totally disagree.” The recom-
mendation was finally accepted if more than two-thirds of the 
panel members answered with “fully agree” or “agree.” After 
the first round, 36 surgeons answered the first Delphi question. 
Consensus was achieved for 65 of the 67 recommendations (97%) 
(Supplementary Table 2). Recommendations that failed to reach 
an agreement by two-thirds were modified according to feedback 
from expert panels and redistributed to second-round panels. In 
Table 1. Interpretation of American College of Physicians grading system
Grade of recommendation Benefit vs. risks and burdens Interpretation Implication
Strong recommendation
   High-quality evidence
   Moderate-quality evidence
   Low-quality evidence
Benefits clearly outweigh risks and 
burden or vice versa.
Strong recommendation, can apply 
to most patients in most  
circumstances without reservation.
Strong recommendation, but may 
change when higher-quality  
evidence becomes available.
For patients: most would want the 
recommended course and only a 
small proportion would not.
For clinicians: most patients should 
receive the recommended course 
of action.
Weak recommendation
   High-quality evidence
   Moderate-quality evidence
   Low-quality evidence
Benefits closely balanced with risk 
and burden.
Uncertainty in the estimates of  
benefits, risks, and burden;  
benefits, risks, and burden may  
be closely balanced.
Weak recommendation, best action 
may differ depending on  
circumstances or patients’ or  
societal values.
Very weak recommendation, other 
alternatives may be reasonable.
For patients: most would want the 
recommended course of action but 
some would not. A decision may 
depend on an individual’s  
circumstances.
For clinicians: different choices will 
be appropriate for different  
patients, and a management  
decision consistent with a patient’s 
values, preferences, and  
circumstances should be reached.
No recommendation
   Insufficient evidence Balance of benefits and risks cannot 
be determined.
Insufficient evidence to recommend 
for or against routinely providing 
the service
For patients: decisions based on  
evidence from scientific studies 
cannot be made. 
For clinicians: decisions based on 
evidence from scientific studies 
cannot be made.
Table 2. Level of evidence
Term Definition
High-quality evidence RCT without important limitations or  
overwhelming evidence from  
observational study 
Moderate-quality evidence RCT with important limitations or strong  
evidence from observational studies
Low-quality evidence Observational studies/case studies
RCT, randomized controlled trial.
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the second round, experts used the same voting methods de-
scribed in the first round, but were aware of group scores and 
comments. The final response was analyzed as described in round 
one, and two recommendations were resolved by consensus on 
the entire panel of experts. The organization of the management 
guideline recommendations is shown in Table 3.
Table 3. Organization of the KSTHNS guidelines of surgical treatment for oral cancer
Location key Section Item
Guidelines for surgical treatment for oral cancer R1
A Diagnosis and work up of oral cancer
   A1 What is the role of a biopsy and physical examination in the diagnosis of oral cancer? R2
   A2 What is the role of assessment of oral function in the treatment planning for oral cancer? R3
   A3 How can we evaluate second primary malignancies in patients with oral cancer? R4
   A4 What is the role of CT in the preoperative evaluation of oral cancer? R5
   A5 What is the role of MRI in the preoperative evaluation of oral cancer? R6
   A6 What is the role of PET/CT in the preoperative evaluation of oral cancer? R7
   A7 What is the role of US in the preoperative evaluation of oral cancer? R8
B Prevention of oral cancer
   B1 What is the role of intervention for smoking and drinking cessation in preventing oral cancer? R9
   B2 What is the role of oral care in preventing oral cancer? R10
C Surgical management of oral cancer according to subsites
   C1 Which approach is appropriate for oral cancer? R11
   C2 Oral tongue cancer
      C2-1 What is the adequate resection margin for oral tongue cancer? R12
      C2-2 What is the influence of tumor thickness on surgery-planning? R13
   C3 Maxillary gingiva and hard palate cancer R14
   C4 Mandibular gingival cancer
      C4-1 What is the adequate resection margin for mandibular gingival cancer? R15
      C4-2 Is mandibulectomy mandatory when oral cancer abuts the periosteum of the mandible? R16
      C4-3 What is the appropriate extent of mandibulectomy to be applied when oral cancer invades the marrow of the mandible? R17
   C5 Floor of the mouth cancer R18
   C6 Buccal mucosa cancer R19
   C7 Retromolar trigone cancer R20
   C8 Neck management for oral cancer
What is the appropriate strategy for the management of cervical lymph nodes in oral cancer?
      C8-1 Management for clinically negative neck (N–) in patients with oral cancer R21
      C8-2 Extent of neck dissection for clinically negative neck (N–) in oral cancer R22
      C8-3 Sentinel node biopsy for clinically negative neck (N–) in oral cancer R23
      C8-4 Management of clinically positive neck (N+) in patients with oral cancer R24
   C9 Reconstruction for oral cancer defects
What are the appropriate reconstruction methods for oral cancer defects?
      C9-1 Soft tissue reconstruction for oral cancer defects R25
      C9-2 Mandibular reconstruction for oral cancer defects R26
D Postoperative follow-up
How can we postoperatively follow-up patients with oral cancer? 
   D1 Long-term follow-up schedules R27
   D2 Tests during the follow-up period R28
   D3 Thyroid function evaluation R29
E Rehabilitation
What are the appropriate rehabilitation and supportive therapy options after anticancer treatment?
   E1 Speech therapy and swallowing rehabilitation R30
   E2 Shoulder rehabilitation R31
   E3 Lifestyle modification R32
   E4 Psychiatric support R33
F Salvage surgery
   F1 What is role of salvage surgery in the recurrent oral cavity cancer? R34
KSTHNS, Korean Society of Thyroid-Head and Neck Surgery; CT, computed tomography; MRI, magnetic resonance imaging; PET/CT, positron emission 
tomography/computed tomography; US, ultrasonography.
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GUIDELINES FOR SURGICAL TREATMENT OF 
ORAL CANCER
Recommendation 1
Decisions regarding treatment for oral cancer patients should 
be made as a result of discussion with the multidisciplinary 
team and sufficient information should be given to patients 
about the role of chemotherapy, radiation therapy and sur-
gery (strong recommendation, high-quality evidence).
A. Diagnosis and work up of oral cancer
A1.  What is the role of a biopsy and physical examination in the 
diagnosis of oral cancer?
Recommendation 2
(A)  Tissue biopsy and histologic examination are essential 
for the diagnosis of oral cancer (strong recommendation, 
high-quality evidence).
(B)  Adjunctive tests are useful but cannot replace traditional 
biopsy for the definitive diagnosis of oral cancer (weak 
recommendation, high-quality evidence).
(C)  Population-based screening programs are necessary to 
reduce oral cancer mortality in high-risk individuals who 
use tobacco, alcohol, or both alcohol and tobacco (strong 
recommendation, high-quality evidence).
(D)  Potentially malignant disorders (PMDs) should be care-
fully followed up (strong recommendation, moderate-
quality evidence).
Early recognition and diagnosis of PMDs (such as erythroplakia, 
leukoplakia, lichen planus, oral submucous fibrosis, discoid lu-
pus erythematosus and actinic keratosis) and oral cancer can 
improve the survival rate and reduce treatment-related morbidi-
ty [8]. Advancements have been made in many technologies for 
the diagnosis of PMD and oral cancer, such vital staining, oral 
cytology, light-based detection, oral spectroscopy, and blood and 
saliva analysis; these details are summarized in Table 4 [9,10]. 
These advances in noninvasive technologies have been reported 
to show various degrees of sensitivity and specificity, and are 
promising for the future development of more effective methods 
for the diagnosis of oral cancer. However, sufficient evidence or 
crucial details were missing to rule out the risk of bias in the 
systematic reviews of these techniques. Therefore, further inves-
tigation with more extensive and exhaustive studies are war-
ranted [9-11]. These advanced techniques may be helpful for 
use as adjunctive tests; however, none of these techniques can 
be recommended as replacements for definitive tissue biopsy. 
All oral lesions should be considered for histologic examina-
tion and clinical impression is not an acceptable alternative to 
definitive biopsy. If this is not good, careful clinical surveillance 
is essential [12]. PMDs have the potential to develop into can-
cers, even though this may take time and the possibility may be 
small. Studies including a long-term follow-up provide evidence 
for the malignant transformation of PMDs. Therefore, it is es-
sential for clinicians to perform regular observation and follow-
up in patients with these conditions [13-15]. Oral cancer is an 
important global health problem with high mortality and mor-
bidity rates. For accurate early detection and treatment, popu-
lation-based screening programs have been introduced. A na-
tion-wide RCT concluded that a visual examination as part of 
an opportunistic population-based screening can reduce the 
mortality rate and improve survival rate with a stage shift for 
high-risk groups who used tobacco, alcohol, or both alcohol and 
tobacco [16-20].
A2.  What is the role of assessment of oral function in the treat-
ment planning for oral cancer?
Recommendation 3
Oral functions such as mastication, speech, and swallowing 
may be assessed preoperatively (weak recommendation, 
moderate-quality evidence).
Table 4. List of the noninvasive technologies for the diagnosis of oral cavity cancer
Diagnostic method Content
Vital staining Toluidine blue, 5% acetic acid, methylene blue, Lugol’s iodine, rose bengal, iodine staining, Tolonium chloride
Cytological techniques Oral brush biopsy (Oral CDx), liquid based cytology, laser capture microdissection
Light-based detection system Tissue fluorescence imaging (VELscope, identafi 3000), chemiluminiscence (ViziLite plus, Microlux/DL,  
Orascoptic-DK), tissue fluorescence spectroscopy (NBI)
Optical biopsy Tissue fluorescence spectroscopy, Raman spectroscopy, elastic scattering spectroscopy, differential path-length 
spectroscopy, nuclear magnetic resonance spectroscopy, confocal reflectance microscopy, optical coherence 
tomography, angle-resolved low coherence interferometry 
Saliva-based oral cancer diagnosis Genomic substances, transcriptomic substances, proteomic substances
Other techniques Molecular analyses (gene alterations, epigenetic alterations, loss of heterozygosity and microsatellite instability,  
viral genome studies, proliferation index and AgNOR analysis, immunohistochemical identification of tumor  
markers), Onco-chips
NBI, narrow band imaging.
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Loss in tissue after oral cavity resection results in a decrease in 
speech, mastication, swallowing, and finally in the patient’s qual-
ity of life. Assessment of these functions can help physicians 
measure the deterioration, and design a restoration plan. Exam-
ples of such assessments include analysis of tongue strength, 
range of motion of the jaw, and salivary production before 
tongue resection, or acoustic measurement before and after ra-
dial forearm free flap reconstruction for tongue defects [21,22]. 
There is a strong correlation between the extent of oral tongue 
and tongue base resection (especially the volume of resection of 
the tongue base) and decrease in swallowing and presence of 
aspiration [23]. Radiation further worsens oral functions such as 
masticatory performance, bite force, and dental state [24].
A prospective study demonstrated that the score significantly 
decreased at 3 months after surgery and gradually improved at 
6 and 12 months. Majority of the patients showed preservation 
of normal or near-normal function at 1-year follow-up [25]. Per-
formance including masticatory function markedly declined with 
mandibulectomy; however free flap mandibular reconstruction 
helped patients regain this function [25-27]. Furthermore, the 
group receiving mandibular reconstruction with prosthetic inter-
vention had better individual functional outcomes [26,28,29].
A3.  How can we evaluate second primary malignancies in 
patients with oral cancer?
Recommendation 4
(A)  The patient with oral cancer is carefully examined to de-
tect second primary malignancies (strong recommenda-
tion, low-quality evidence).
(B)  Additional modalities are recommended for second pri-
mary malignancy (SPM) screening, such as positron emis-
sion tomography/computed tomography (PET/CT), chest 
CT, and panendoscopy (except bronchoscopy) (strong 
recommendation, moderate-quality evidence).
Head and neck squamous cell carcinoma (HNSCC) is associated 
with a high rate of SPM [30-33]. Tobacco smoking, alcohol use, 
betel nut chewing, human papilloma virus (HPV) infection, and 
several genetic predispositions contribute to increased risk of SPM 
in patients with HNSCC [34]. The reported annual incidence of 
SPM in HNSCC patients is approximately 3% to 7%. In a pooled 
analysis of 13 cancer registries, the 20-year cumulative risk for 
SPM was 36% [35]. These SPMs were predominantly located in 
the head and neck, lung, or esophagus. The incidence and location 
of SPMs varied with the subsite location of the primary HNSCC. 
SPMs occurred more frequently in patients with laryngeal or 
hypopharyngeal cancer than in those with oral or oropharyngeal 
cancer, in a Korea Central Cancer Registry [30]. Lung SPM was 
more common in laryngeal cancer, and head and neck SPM was 
more common in oral cancer, as per databases of the Memorial 
Sloan-Kettering Cancer Center [36]. In addition, the risk of esoph-
agus SPM was higher in oral or pharyngeal cancer than in laryn-
geal cancer, as per the Taiwan Cancer Registry [33].
SPMs have a significantly negative impact on the prognosis of 
HNSCC [37-39]. Overall survival (OS) in oral cancer patients 
with simultaneous SPM was significant lower than in those 
without simultaneous SPM (53% vs. 69%, 5-year OS) [38,39]. 
OS with head and neck SPMs was better than that with non-
head and neck SPMs in patients with tongue or laryngeal cancer 
(39% vs. 29%, 5-year OS) [40]. Early detection and proper 
treatment planning of SPMs has an important impact on prog-
nosis [41,42]. The prognosis of HNSCC patients with early stage 
SPM of the esophagus was comparable to that in those without 
esophagus SPM, in contrast to the prognosis of patients with ad-
vanced stage SPM of esophagus [42]. Taken together, patients 
with HNSCC including oral cancer should undergo active sur-
veillance for the early diagnosis of SPMs.  
18F-labeled fluoro-2-deoxyglucose (FDG)-PET/CT has good 
diagnostic performance in detecting SPMs in patients with HN-
SCC. In a meta-analysis, PET/CT showed good sensitivity and 
specificity to detect distant metastases and SPMs for all other 
subsites of HNSCC [43]. Routine flexible or rigid panendoscopy 
of the upper aerodigestive tract including laryngopharyngosco-
py, tracheobronchoscopy, and esophagoscopy for SPM surveil-
lance has been supported by several studies [44-46]. In HNSCC, 
6.4% of synchronous SPMs were clinically silent or were only 
revealed by panendoscopy [44]. There was a relatively high 
chance of detection of esophagus SPMs through panendoscopy 
in patients with oral, oropharyngeal, and hypopharyngeal can-
cer (odds ratio, 55.3) [45]. Whether PET/CT can replace panen-
doscopy is controversial. Regarding synchronous T1 and Tis su-
perficial upper gastrointestinal cancers, PET or PET/CT detected 
only 9.3% of cancers, revealing the limitation of PET/CT for the 
detection of small or superficial mucosal cancers [47]. In con-
trast, Haerle et al. [48] reported that FDG/PET was superior to 
panendoscopy, especially for peripheral lung SPMs. Similarly, 
chest CT was superior to bronchoscopy and chest X-ray for the 
detection of lung SPMs [49,50]. Bronchoscopy was limited to 
the detection of most pulmonary parenchymal nodules diag-
nosed on chest CT. Importantly, screening with chest X-ray in 
asymptomatic patients did not improve survival in HNSCC pa-
tients who developed lung SPMs [51]. Therefore, concurrent 
evaluation of FDG-PET and/or chest CT, and panendoscopy ex-
cept bronchoscopy may be the most sensitive strategy for de-
tecting SPMs in patients with HNSCC. 
A4.  What is the role of CT in the preoperative evaluation of 
oral cancer?
Recommendation 5
Contrast-enhanced CT is recommended for the staging and 
pretreatment evaluation of oral cancer (strong recommenda-
tion, moderate-quality evidence).
KSTHNS et al. Guidelines for Surgical Management of Oral Cancer    113
pretreatment evaluation of oral cancer (strong recommenda-
tion, moderate-quality evidence).
CT with contrast enhancement is a one of the most commonly 
used cross-sectional imaging modalities in the staging of oral 
cancer. CT can provide information on primary tumor extent, 
cervical lymph node metastasis, and bone involvement with 
short scan times [52]. CT showed good sensitivity, specificity, 
and accuracy (61%, 100%, and 66%, respectively) for detecting 
a primary tumor in oral cancer [53]. However, due to low soft 
tissue resolution of CT, magnetic resonance imaging (MRI) is re-
garded as more suitable for assessing primary tumor and soft 
tissue details, compared to conventional CT. Also, CT is more 
prone to metal artifacts and risk of radiation exposure [54]. CT 
generally showed high accuracy for detecting bony involvement 
[55-57]. Handschel et al. [57] reported that modern multislice 
(1–2 mm) CT was a valuable tool for surgical planning in oral 
cancer. In a systematic review, cone beam CT showed high ac-
curacy (95.7%) in detecting mandible invasion [58]. Therefore, 
CT is thought to be useful in RMT, gingiva, lip, and buccal can-
cer, which are more susceptible to bone invasion than other 
sites. Contrast enhanced CT showed similar efficacy in detecting 
metastatic lymph nodes compared to MRI [53,59-61]. In a re-
cent meta-analysis, Liao et al. [60] reported that modern imag-
ing modalities including CT, MRI, ultrasonography (US), and 
PET had similar high sensitivity and specificity. Also, they con-
cluded that CT and MRI are recommended modalities for the 
staging of oral cancer, because CT and MRI can evaluate prima-
ry tumor and cervical nodal status concurrently.
A5.  What is the role of MRI in the preoperative evaluation of 
oral cancer?
Recommendation 6
MRI is recommended for the staging and pretreatment eval-
uation of oral cancer (strong recommendation, moderate-
quality evidence).
MRI is widely accepted to provide excellent soft tissue resolu-
tion compared to conventional CT. Thus, in oral cancer where 
soft tissue involvement extent is important, MRI is more appro-
priate for accurate T-staging [53,54,62,63]. MRI has high sensi-
tivity and specificity in assessing soft tissue involvement and 
bone invasion as well as in detecting lymph node metastasis 
[8,64]. Ng et al. [65] reported that PET is very sensitive to de-
tecting primary tumors, but does not provide sufficient informa-
tion for surgery planning. They further concluded that CT and 
MRI are methods of choice in staging oral cancer, though PET 
may be of value. In the evaluation of tumor thickness, preopera-
tive MRI thickness tended to agree strongly with histologic 
thickness [66,67], but the preoperative MRI threshold was sig-
nificantly higher than the histologic thickness [67]. In assessing 
bone invasion, MRI generally showed high sensitivity (58.3% to 
94%), specificity (97.1% to 100%), and accuracy (86% to 
87%) [58,68,69] CT also showed good sensitivity (47.1% to 
83%), specificity (82% to 100%), and accuracy (81% to 87%). 
In a systematic review, MRI, panoramic X-ray, PET-CT, and cone 
beam CT had high accuracy in detecting mandibular invasion 
[54,58]. In assessing cervical lymph node metastasis, CT and 
MRI showed equivalent ability to detect metastatic lymph 
nodes. In a study which analyzed 29 studies, both MRI and CT 
showed good sensitivity (24% to 79%) and specificity (31% to 
89%) [70]. In a meta-analysis by Liao et al. [60], MRI, CT, US, 
and PET were found to show similar sensitivities and specifici-
ties in detecting metastatic lymph nodes.
MRI provides excellent soft tissue detail without radiation ex-
posure and is less affected by metal artifacts [54,70,71]. MRI 
has disadvantages related with motion artifacts due to relatively 
long scanning time; however, because it is less affected by me-
tallic artifacts, MRI should be considered first for accurate T-
staging in cases where metal artifacts are expected [52,54]. 
A6.  What is the role of PET/CT in the preoperative evaluation 
of oral cancer?
Recommendation 7
PET/CT is recommended for oral cancer assessment, espe-
cially at advanced stages, because it is superior to traditional 
CT or MRI in terms of accurate detection of regional/distant 
metastases and second primary cancers. It is useful to rule 
out mandibular marrow invasion (strong recommendation, 
moderate-quality evidence).
PET is a functional imaging technique which detects tumors 
with high metabolic activity. PET/CT is a fusion of functional 
imaging from PET and anatomic imaging from CT. Thus with 
PET/CT, functional information from PET can be more precisely 
correlated with anatomic details from CT. This technique is very 
sensitive in detecting primary and recurrent malignant tumors 
in the head and neck [72]. The National Comprehensive Cancer 
Network clinical practice guidelines for head and neck cancer 
recommend FDG-PET/CT in the preoperative staging of ad-
vanced (stage III and IV) oral cavity, oropharynx, hypopharynx, 
and larynx cancers. PET is known to have lower resolution 
compared to CT and MRI in outlining certain parameters essen-
tial for surgical planning such as anatomic details and the extent 
of a tumor. However, some studies have shown that PET has 
higher sensitivity than CT and MRI in the visualization of clini-
cally proven primary tumors [73,74]. 18F-FDG PET has higher 
sensitivity (100%) than CT (68.2%) in detecting primary tu-
mors with high metabolic activity [75,76]. 
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Stuckensen et al. [77] prospectively compared PET, US, CT, 
and MRI in assessing metastatic cervical lymph nodes of 106 
patients with oral SCC. They found that PET showed the highest 
specificity (82%) on the N stage, while US had the highest sen-
sitivity (84%). Ng et al. [65] compared PET with CT/MRI in the 
evaluation of primary tumors and metastatic cervical lymph 
nodes of 124 oral cancer patients. The sensitivity of PET (75%) 
to assess nodal metastases by level was significantly higher than 
that of CT/MRI (53%), while PET specificity (93%) was similar 
to CT/MRI (95%). 18F-FDG PET/CT is a useful tool for staging 
and restaging head and neck cancers and can simultaneously 
detect regional recurrence, distant metastases, and possible sec-
ond primary tumors with high sensitivity and specificity [78]. 
PET/CT can be used in assessing mandibular invasion of oral 
cancer. Generally, CT has shown high accuracy for detecting 
cortical erosion of the mandible in oral cancer [55-57]. In assess-
ing mandible or maxilla bone marrow involvement of oral can-
cer patients, PET/CT showed higher specificity than did MRI 
(83% vs. 61%, respectively; P=0.0015) but lower sensitivity 
(78% vs. 97%, respectively; P=0.0391) [79]. In another study, 
PET/CT was comparable to CT and MRI in specificity for de-
tecting mandibular invasion, and furthermore, by combining 
these imaging modalities, sensitivity was improved [68]. 
A7.  What is the role of US in the preoperative evaluation of 
oral cancer?
Recommendation 8
US can be used to evaluate cervical nodal status for oral can-
cer staging (weak recommendation, low-quality evidence).
US is a reliable and valuable tool for evaluation of lymph node 
metastasis in head and neck cancer patients [80]. US has several 
advantages in head and neck cancer assessment over other im-
aging techniques, as it is widely available, well tolerated by pa-
tients, radiation-free and cost effective, and can be combined 
with a US-guided fine needle aspiration [81,82]. In particular, 
intraoral US has been found to be useful in oral tongue cancer. 
Vascularity assessment using intraoral US Doppler was found to 
be helpful in predicting pathologic grade of primary tumors and 
cervical node metastasis in oral tongue cancer patients [83]. 
When 18F-FDG, US, CT, and MRI results in patients with prov-
en oral cancer were compared with the postoperative histologic 
tissue evaluation, the US technique showed the highest sensitiv-
ity (84%) and accuracy (76%), but lowest specificity (68%) [77]. 
Lodder et al. [84] have compared tumor thickness measured by 
intraoral US with histopathologic analysis. They found that when 
tumor thickness measured by intraoral US was less than 7 mm, 
the risk of lymph node metastasis was 12%. However, when tu-
mor thickness as per intraoral US exceeded 7 mm, the risk of 
lymph node metastasis was increased to 57% (P=0.001). 
B. Prevention of oral cancer
B1.  What is the role of intervention for smoking and drinking 
cessation in preventing oral cancer?
Recommendation 9
Intervention for smoking and drinking cessation should be 
recommended for high-risk populations (strong recommen-
dation, high-quality evidence). 
Various lifestyle, environmental, and host factors are implicated 
in oral carcinogenesis. The most important risk factor for oral 
cancer is smoking [62]. The association between oral cancer and 
smoking is dose-dependent. The risk for cancer development is 
proportional to the amount and duration of smoking. Smokers 
who do not have coexisting risk factors do not appear to be at 
higher oral cancer risk than are nonsmokers, while heavy smok-
ers have a higher risk of oral cancer. The risk of oral cancer in-
creases significantly when the smoking period is more than 20 
years and the frequency of smoking is higher than 20 cigarettes 
per day [85]. 
Alcohol is another important cause of oral cancer and ac-
counts for a large proportion of oral cancer deaths. It is known 
that about 7%–19% of oral cancer cases are caused by heavy 
alcohol drinking [86]. Alcohol consumption has been shown to 
act synergistically with smoking to increase the risk of develop-
ment of oral cancer. Despite this strong association, the exact 
pathogenesis of alcohol for oral cancer is not completely under-
stood. Malnutrition and the deficiency of vitamins and minerals 
due to chronic alcohol consumption may also influence carcino-
genesis.
HPV is an important risk factor for the development of ano-
genital cancer. Recently HPV has been regarded as a cause of 
head and neck cancer, predominantly that of the oropharynx 
including the tonsils, the base of the tongue, and the other phar-
ynx [87]. HPV-positive tumors have a risk factor associated with 
sexual behavior in contrast to HPV-negative cancer. HPV-nega-
tive cancers are associated with smoking and alcohol consump-
tion [88]. HPV-positive tumors rarely occur in the oral cavity. 
The role of HPV in oral cancer has yet to be determined [89]. 
However, recent evidence suggested that the outcome for nono-
ropharyngeal HPV-positive patients is better compared to that 
of their HPV-negative counterparts; additional studies are need-
ed to verify the correlation between HPV infection and the inci-
dence of oral cancer. Vaccination for HPV is not recommended 
to prevent oral cancer due to little evidence.
B2. What is the role of oral care in preventing oral cancer?
Recommendation 10
Regular oral health maintenance and routine dental care are 
recommended to prevent oral cancer (strong recommenda-
tion, high-quality evidence).
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recommended to prevent oral cancer (strong recommenda-
tion, high-quality evidence).
Poor oral hygiene and dental status, and chronic oral ulceration 
have been suggested to promote neoplasms in patients with 
other risk factors such as smoking and consumption of alcohol. 
Evidence to evaluate the influence of dental factors on oral can-
cer development is challenging due to confounding effects of 
lifestyle, and socioeconomic and cultural characteristics. A 2–5 
fold higher oral cancer risk has been reported for patients with 
periodontal disease, as compared to that for patients without 
periodontal disease [90]. Chronic inflammation caused by in-
flammatory cells and periodontal pathogens may add to the 
burden of oral cancer [91,92]. The risk of oral cancer was signifi-
cantly lower in patients with oral health maintenance and den-
tal care than in those without [93,94]. This further enhances the 
need for oral health education programs related to routine oral 
health care and routine dental care to prevent oral disease, in-
cluding oral cancer. 
C. Surgical management of oral cancer according to subsites
C1. Which approach is appropriate for oral cancer?
Recommendation 11
(A)  Surgeons should choose the appropriate surgical ap-
proach to achieve a clear surgical margin based on tumor 
size, depth location, degree of mouth opening, mandibu-
lar invasion, and the surgeon’s experience (strong recom-
mendation, low-quality evidence).
(B)  For advanced oral cancers, mandibulotomy with or with-
out lip-split can produce wide exposure, but may cause 
morbidities (weak recommendation, moderate-quality 
evidence).
Choosing the method of surgical approach is the first step in 
planning surgery for oral cancer. The goal should be to achieve 
adequate clear surgical margins and long-term survival. There-
fore, parameters such as location and extent of invasion, depth 
of infiltration, and proximity to the mandible or maxilla should 
be used to guide surgical decisions. Oral cavity conditions such 
as trismus, dentition, tongue mobility, and the size of the oral 
aperture, and other factors such as dentition, size of the oral ap-
erture, degree of mouth opening, and the size and mobility of 
the tongue should also considered while selecting the surgical 
method. Surgery for oral cancer often leads to unaesthetic pa-
tient appearance and functional problems, so surgery should 
also be aimed at preserving functions such as speech, swallow-
ing, and deglutition, in addition to reducing scarring [95,96].
A transoral (peroral) approach is recommended for small, an-
teriorly located, and easily accessible tumors which are located 
to the oral tongue, FOM, gum, cheek mucosa, and the hard pal-
ate. However, this approach may not be useful for deeply infil-
trating and/or posterior located cancers and/or in patients with 
trismus and/or obstructive dentition.
For advanced oral cancers, lip-splitting and/or mandibulotomy 
should be considered, to obtain a clear surgical margin. The low-
er cheek flap approach requires a midline lip-splitting incision 
which is continued laterally into the neck, for exposure and 
neck dissection (ND). Except for tumors of the upper gum and 
hard palate, this approach provides excellent exposure for near-
ly all tumors of the oral cavity. The upper cheek flap approach is 
optimal for the resection of larger tumors of the hard palate and 
the upper alveolus, particularly if located posteriorly. The man-
dibulotomy approach usually involves a lip-split, and has been 
preferred for advanced oral cancer because it can provide excel-
lent exposure to the oral cavity and the oropharynx [97,98]. 
Compared to midline mandibulotomy, a paramedian mandibu-
lotomy has merits for swallowing function since it preserves the 
geniohyoid and genioglossus muscles, and the anterior belly of 
the digastric muscle [99]. Paramedian mandibulotomy is an ex-
cellent surgical approach for access to large posteriorly located 
lesions of the oral cavity. However, mandibulotomy may lead to 
many unfavorable complications such as exposure of metal fixa-
tion plate, fistula formation, fixation failure, osteonecrosis after 
radiation treatment, and unsatisfying appearance [100,101]. 
Due to interruptions of the mandibular continuity, disturbances 
of oral functions and temporomandibular joint problems can oc-
cur [102,103]. 
Therefore, to reduce such problems in cases without mandibu-
lar involvement, several methods of mandibular preservation 
such as the visor flap approach and the mandibular lingual re-
lease have been suggested. In a study comparing the mandibu-
lotomy and mandibular lingual release approaches, no differ-
ences were observed in clinical outcomes and functions when 
the primary oral cancer was under 5.1 cm, and was anteriorly 
located [96]. A recent meta-analysis comparing mandibulotomy 
and mandibular preservation methods concluded that mandibu-
lar sparing may provide a similar clinical outcome of surgical 
margins and survival [104]. However, the mandibular-sparing 
group showed a lower complication rate compared to the man-
dibulotomy group. The authors recommended the mandibuloto-
my approach over mandible-sparing in cases with involvement 
of the maxilla, upper gingiva, hard/soft palate, or a combination 
of multiple anatomic structures [95,105,106]. 
C2. Oral tongue cancer
C2-1. What is the adequate resection margin for oral tongue cancer?
Recommendation 12
(A)  The macroscopic and palpable margin should be at least 
10 mm from the edge of the tumor (weak recommenda-
tion, low-quality evidence).
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(B) When a microscopic residual tumor or a close margin is 
identified, re-resection or adjuvant treatment should be con-
sidered (strong recommendation, low-quality evidence).
Surgical margin was an independent prognostic factor that af-
fected disease-free survival and local recurrence [107-112]. Ob-
taining adequate margin during surgical excision may improve 
these outcomes. The 5-year and 10-year OS rates were 72% and 
64%, respectively, in patients with clear surgical margins, com-
pared with 21% and 0, respectively, in those with involved mar-
gins [108]. Traditionally, a 1-cm margin is taken in all planes 
around a macroscopic or palpable oral tongue cancer [107,109-
112]. Pathologists and clinicians have agreed to define involved 
margins as less than 1 mm and close margins as 5 mm or less, 
and to designate margins greater than 5 mm as clear [107,108, 
111,112]. The pathological margins were reported to be much 
smaller than those expected by the surgeons; this is largely due 
to margin shrinkage by about 20%–25% following resection, 
and further loss of about 10% on formalin fixation [113]. So, 
formalin fixation and slide preparation reduced mucous margin 
by approximately 30%–50%. This results in a final pathological 
margin of approximately 5 mm for tumors with surgeon-mea-
sured margins of 1 cm. The tumor resection margin was an im-
portant predictor for recurrence, with statistically significant 
higher recurrence rate for resection margins <5 mm as com-
pared to that for margins >5 mm. The significance was main-
tained for resection margins <10 mm. On multivariate analysis, 
lower recurrence rates was noted for margins >5 mm compared 
to those for margins <5 mm. This has led to improved disease-
specific survival rates in patients with margins >5 mm [107]. 
However, several studies have reported that the surgical margin 
was not related patient prognosis [3,114]. Ganly et al. [114] re-
ported that the surgical margin involved by the tumor did not 
affect the OS of patients in multivariate analysis. Surgical mar-
gin status was related to disease-specific survival and recurrence-
free survival in univariate analysis. Other studies have reported 
that the recurrence of oral tongue cancer with an epithelial posi-
tive margin was seen only at the primary lesion, and that not all 
cases showed local recurrence; furthermore, the time for the re-
currence was considerably longer, all of the recurrence cases 
could be treated with additional resection, and there was no 
prognostic difference [3]. Intraoral intraoperative US was found 
to be an accurate and reliable tool for assessing tumor-free deep 
margin during surgery [115]. 
C2-2. What is the influence of tumor thickness on surgery-planning?
Recommendation 13
(A)  Tumor thickness should be considered when determining 
the extent of surgery because it is closely related to local 
recurrence of the primary tumor and to cervical lymph 
node metastasis (strong recommendation, moderate-
quality evidence).
       recurrence of the primary tumor and to cervical lymph 
node metastasis (strong recommendation, moderate-
quality evidence).
(B)  Tumor thickness should be assessed to ensure adequate 
deep resection margin of oral tongue cancer, and the 
evaluation of tumor thickness can be made through pal-
pation, preoperative imaging studies, and intraoperative 
US (strong recommendation, moderate-quality evi-
dence).
Because the oral tongue is mainly composed of muscle tissue 
and there is no anatomic boundary to prevent the tumor spread, 
oral tongue tumors spread more easily than do tumors at other 
oral cavity subsites. Thus, it is difficult to accurately evaluate the 
extent of tumor thickness before surgery. Completion of surgical 
resection with adequate safety margins has a substantial effect 
on treatment outcome and prognosis [116,117]. However, in the 
case of oral tongue cancer, it is very difficult to predict the de-
gree of tumor thickness by gross inspection and palpation before 
surgery. The most challenging area to obtain adequate safety 
margins during surgical resection of oral tongue cancer is the 
basal area of the tongue.
In general, since surgical resection of the oral tongue starts 
from the surface of the oral tongue cancer, insufficient or close 
resection margins are commonly confirmed in the basal area of 
oral tongue cancer on pathologic specimen. Inadequate safety 
margins at this site and the thickness of the tumor are closely 
related to local relapse of the primary tumor and to cervical 
lymph node metastasis [118,119]. In a study comparing tumor 
thickness and the frequency of lymph node metastasis in oral 
tongue cancer, a 26% occult lymph node metastasis rate was re-
ported in patients with a tumor thickness of 2 mm or more. A 
similar study reported that there was a significant difference in 
lymph node metastasis as per the criterion of 4–7.5 mm, and 
the authors insisted that a prophylactic ND was needed in all 
the cases except superficial cancer cases [120-123].
In the newly revised American Joint Committee on Cancer 
(AJCC) 8th edition, the concept of depth of invasion (DOI) was 
introduced in the T classification method, and T1 was defined as 
<5 mm, T2 was defined >5 mm, and T3 was defined >10 mm 
[124]. DOI is histologically the distance from the basement 
membrane of the surrounding normal tissue to the deepest part 
of the tumor. However, as it is difficult to evaluate DOI intraop-
eratively, tumor thickness should be assessed by palpation, pre-
operative imaging studies, or by intraoperative US [115]. If post-
operative histopathologic examination shows a significant DOI 
or insufficient deep safe resection margin, additional treatment 
such as additional resection, prophylactic cervical lymphadenec-
tomy, and radiation therapy should be considered.
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C3. Maxillary gingiva and hard palate cancer
Recommendation 14
(A)  Mucosal/periosteal resection is recommended primarily 
for lesions without bone invasion (strong recommenda-
tion, low-quality evidence).
(B)  Partial resection of the maxillary bone is recommended 
primarily for lesions with bone invasion (strong recom-
mendation, low-quality evidence).
Many studies have revealed the importance of margin status as 
an outcome predictor in oral cancer. Such studies have suggest-
ed that a margin of ≥5 mm on final pathology was adequate 
[125]. However, cancers in the maxillary gingiva and hard palate 
regions are rare compared to cancers at other oral cavity subsites; 
this has led to a paucity of evidence regarding the management 
and outcome for cancers occurring at these subsites. Data on 
treatment guidelines in this patient population are limited [126]. 
Superficial erosion of the bone or tooth socket in gingival 
cancer is not sufficient to classify the tumor as T4, but gingival 
cancer that invades the underlying bone is designated as T4. 
Since bone is close to the musculoskeletal, gingival cancer tends 
to invade bone early, so it should be classified as T4 in the pre-
sentation. As a result, most operations for gingival cancer in-
volve removal of bone structures [127]. However, one systemat-
ic review suggested that small lesions without bone invasion are 
rare, but can be treated with only mucosal or periosteal resec-
tion [128]. 
Attachment of the hard palate mucosa to the underlying peri-
osteum is different from that of the gingival mucosa. The hard 
palate is a unique anatomic site because it has an abundance of 
minor salivary glands. Consequently, hard palate cancer tends 
to invade the bone later than does gingival cancer. Surgery of 
hard palate cancer frequently does not include removal of the 
underlying bone [129]. However, management guidelines spe-
cifically pertaining to hard palate cancer are based on expert 
opinion owing to scant evidence [130]. Enucleation is avoided 
for hard palate cancer because it is associated with a high risk of 
recurrence whether enucleation is safe for hard palate cancer re-
mains unknown [131].
The extent of maxillary gingival and hard palate surgery is 
dependent on the size and growth of the tumor. There are vari-
ous types of partial resection modes used for the maxillary 
bone, i.e., alveolectomy, infrastructure maxillectomy, and pala-
tectomy. Among them, infrastructure maxillectomy involves the 
resection of the maxillary floor below the level of the infraorbit-
al nerve, gingiva arch, hard palate, and the lower lateral nasal 
wall [132]. However, maxillectomy may induce functional dis-
comfort. Due to the proximity of the maxillary sinuses, the sur-
gery of upper gingival cancer often leads to oroantral fistulas, 
which may require subsequent surgical or nonsurgical recon-
struction. Some studies have reported that margins of <5 mm 
are associated with significantly higher local recurrence rates 
than are margins of ≥5 mm in oral cancer. However, no study 
has focused on the gingiva or the hard palate. Nevertheless, the 
effects of 5-mm margins were similar across all oral cavity sub-
sites in many studies [125]. 
C4. Mandibular gingival cancer
C4-1.  What is the adequate resection margin for mandibular gingival 
cancer?
Recommendation 15
(A)  Mucosal/periosteal resection is recommended primarily 
for lesions without bone invasion (strong recommenda-
tion, low-quality evidence).
(B)  Maintenance of a bone margin of at least 10 mm is nec-
essary in mandibulectomy (weak recommendation, low 
quality evidence).
In case of the mandibular gingival cancer, selection of the surgi-
cal resection depends on the stage of disease, the need for man-
dibular resection or ND, and the method of reconstruction. Re-
cent trends in treatment focus on preservation of mandibular 
function due to its critical involvement in maintaining aesthetic 
and psychological aspects of the patient [133]. There are several 
resection approaches available. Similar to the maxillary gingiva, 
mandibular gingival cancer without bone invasion is rare, but 
the tumor is usually removed by gingival mucosal resection [128]. 
Studies of mandibular gingiva are mainly either retrospective or 
case reports, and the mandibular gingiva is often studied togeth-
er with the other oral cancer subsites; thus mandibular gingival 
subsite-specific analysis is difficult. In the future, studies focused 
on gingival cancer will help provide a better basis for conclusions 
of treatment and outcomes. Even if the study evaluates a broad-
er oral cancer population, gingival subsite analysis is needed to 
better understand this separate disease entity.
Although more than 5 mm of histopathologically uninvolved 
tissue margin from the resected tumor is usually regarded as a 
negative margin in oral cancer, most studies of “margin tissue” 
have included an evaluation of bone tissue. Soft tissues includ-
ing mucosa shrink to varying extents once removed from the 
original sites; however, due to the hardness of this tissue type, 
planning the placement of 5-mm resection margins in bone is 
not a tenable option. Furthermore, the exact location of the tu-
mor in the bone may be unclear and lead to ambiguity in the 
application of bone margin. 
McGregor and MacDonald [134] recommended a resection of 
5 to 10 mm of uninvolved bone around the tumor, and other 
researchers have suggested removal of at least 10 mm of unaf-
fected bone in the case of macroscopic tumors with suspected 
bone involvement [135-137]. Intraoperative histologic evalua-
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tion of bone margins by frozen section analysis may provide 
critical information during mandibulectomy, but it is presently 
not practical in real-world settings because of the necessity of 
decalcification procedures before identification of the bone mar-
gin. Some authors have suggested intraoperative cytologic scrap-
ings of the mandibular bone marrow to estimate the bone mar-
gin, and have demonstrated excellent correlations with the actu-
al pathologic status of the bone margin [135,138]. 
In principle, a positive bone margin involved by cancer in-
creases risk of morbidity; this may influence postoperative addi-
tional treatment plans, and lead to an unfavorable prognosis. 
However, as previously discussed, low impact of the pathologic 
status of a bone margin on local disease control and survival 
outcomes may not justify implementation of such a safety mar-
gin on mandibular resection. A subsequent question pertaining 
to safety margins in mandibulectomy concerns the extent to 
which the buttress of the remnant mandible should be preserved 
in the case of marginal mandibulectomy. Barttelbort and Ariyan 
[139] compared the amount of residual bone necessary to with-
stand fracture in marginal mandibulectomy. The authors per-
formed incremental osteotomies on fresh cadaver mandibles by 
applying incremental weights. They proved that at least 1 cm of 
bone at the inferior border of the mandible should be kept to 
reduce the risk of fracture in marginal mandibulectomy. Accord-
ing to the report, surgeons may reinforce the remaining mandi-
ble with reconstruction plates if the height of nonviolent bones 
is less than 10 mm [140]. 
C4-2.  Is mandibulectomy mandatory when oral cancer abuts the peri-
osteum of the mandible?
Recommendation 16
(A)  Mandibulectomy can be waived if the tumor abuts the 
periosteum of the mandible (weak recommendation, low 
quality evidence).
(B)  Mucosal/periosteal resection can be considered for le-
sions without bone invasion (weak recommendation, low 
quality evidence).
Mandibular invasion in oral cancer is an important determinant 
of the manner of reconstruction as well as the extent of resec-
tion. Management of the mandible is a very important part of 
oral cancer surgery in terms of complete tumor removal and 
limiting aesthetic and functional deficits (such as chewing and 
phonation). 
Prior to mandibulectomy, it should be determined whether 
the mandible is actually invaded or if it merely abutted by the 
tumor. If violation of the mandible by the tumor is obvious, it is 
important to determine whether only the cortex is invaded or if 
the medulla or an alveolar nerve are involved as well. In addi-
tion, in cases of recurrence, it is necessary to grasp the status of 
the adjacent tooth and that of previous treatment including sur-
gery or radiotherapy (RT), prior to performing mandibulectomy 
and reconstruction. 
The judgement of the extent (marginal versus segmental) of 
surgery and the plan to include safety margins are important for 
oncological safety during mandibulectomy. Finally, reconstruc-
tion considering both aesthetic and functional aspects is critical 
to the patient’s quality of life. For this reason, choice of graft 
materials should be made with caution, and preoperative simu-
lation of reconstruction should be performed using computer-
aided design and manufacturing systems. This section addresses 
recommendations about resection and reconstruction of the 
mandible in oral cancer.
Accurate preoperative assessment along with the comprehen-
sion of the spreading pattern and invasion routes is essential to 
determine the optimal level and extent of mandibulectomy in 
oral cancer. Clinical evaluation of mandibular invasion is per-
formed by bimanual assessment of the cortical thickening or 
fixity of the tumor mass in relation to the mandible. Inferior al-
veolar nerve paresthesia or pathological fractures are also highly 
suspicious signs of mandible invasion. According to a recent re-
view article, clinical evaluation carries a sensitivity ranging from 
32% to 96% [141]. There is no consensus regarding the most 
reliable imaging modality for the identification of mandibular 
involvement in oral cancer. There have been no investigations 
into methods for predicting mandible invasion with 100% reli-
ability. Various imaging techniques including plain radiography, 
CT, MRI, bone scans, single photon emission CT, and PET/CT 
have been used with varying degrees of sensitivity and specifici-
ty (Table 5) [140-142]. 
Another point for consideration in the assessment of mandi-
ble invasion is the pattern of tumor infiltration to the bone. It 
has been known that there are two invasion patterns of oral 
cancer to the mandible. In the infiltrative pattern, digits and is-
lands of tumor advance independently into the cancellous spac-
es. In the erosive pattern, the tumor propagates on a broad front 
with a connective tissue layer and active osteoclasts can be seen 
separating the tumor from the bone [143]. Wong et al. [144] 
Table 5. Summary and comparison of the imaging techniques in de-
tecting mandible invasion of oral cavity cancer
Imaging modality Sensitivity (%) Specificity (%)
Plan radiography 79.0 (57–97) 80.6 (64–97)
CT  75.8 (50–100) 95.7 (57–97)
MRI  80.1 (39–100) 79.1 (50–96)
Bone scintigraphy  93.4 (71–100) 70.5 (41–88)
SPECT  98.2 (97–100) 63.2 (29–92)
PET/CT  93.3 (80–100) 61.0 (14–85)
Values are presented as mean (range).
CT, computed tomography; MRI, magnetic resonance imaging; SPECT, 
single photon emission computed tomography; PET/CT, positron emission 
tomography/computed tomography.
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studied survival in relation to cancer invasion patterns and 
found that the 3-year recurrence-free survival in the infiltrative 
pattern group was 30%, compared with 73% in the erosive pat-
tern group. Shaw et al. [145] demonstrated that the infiltrative 
pattern was related to significantly higher local recurrence rates 
and lower cancer-specific survival rates compared to erosive pat-
terns. Intriguingly, the authors identified no statistical difference 
in local recurrence or survival compared to patients with the 
erosive pattern regardless of bony involvement histologically. 
Therefore, in the assessment of tumor invasion to the mandible 
with subsequent decision-making on mandibulectomy, tumor 
invasion patterns should also be considered.
The management of a mandible which is not definitely invad-
ed but is just abutted by oral cancer is usually subjected to re-
section rather than to preservation or stripping. Shaha [146] in-
sisted that whenever the tumor is close to the mandible or is ad-
herent to the periosteum, marginal mandibulectomy should be 
considered. Muscatello et al. [147] in their reports about 56 pa-
tients who underwent marginal mandibulectomy also concluded 
that whenever the tumor was close to the mandible or adhered 
to the alveolar periosteum, marginal mandibulectomy could be 
an oncological sound procedure, although infiltration of the re-
sected bone was detected in only one patient (1.8%). 
It is relevant to evaluate the actual correlation between the 
number of clinically suspicious cases of mandible invasion and 
that of cases with real pathologic involvement. Pandey et al. 
[148] performed a prospective study of 51 patients with oral 
cancer with suspicious mandibular bone involvement and who 
subsequently underwent segmental- or hemimandibulectomy. 
After resection, the mandible was decalcified and sectioned seri-
ally at 0.5-cm intervals to determine bone invasion, and man-
dibular invasion was identified in 25 of 51 patients (49%). Sur-
geons are often inclined to perform mandibulectomy to avoid 
under-treatment (i.e., positive margin) even in cases of tumor 
abutment to the mandible; however, a review article demon-
strated relatively high percentages (35%–78%) of cases with no 
evidence of mandibular invasion in the resected mandibles; such 
surgeries often result in considerable cosmetic and functional 
defects [141]. Additionally, the prognostic impact of mandibular 
invasion by oral cancer is controversial, and there have been re-
ports of decreased survival rates and increased recurrence with 
bone invasion as well as reports of decreased survival rates in-
dependent of bone invasion [141].
To clearly prove the validity of mandibulectomy in abutment 
cases, a RCT comparing the local control rate of oral cancer be-
tween mandibulectomized and mandible-preserved patients is 
needed; however, neither clinical trial reports nor reports of ac-
tive surveillance have been published in literature. In summary, 
it is necessary to identify mandibular involvement in the man-
agement of oral cancer by combined physical exam and imaging 
modalities. Additionally, tumor invasion patterns should also be 
considered with subsequent planning on mandibulectomy. How-
ever, in cases where the periosteum of the mandible is abutted 
by the oral tumor, the necessity and validity of mandibulectomy 
is unclear. 
C4-3.  What is the appropriate extent of mandibulectomy to be applied 
when oral cancer invades the marrow of the mandible?
Recommendation 17
(A)  Marginal mandibulectomy is recommended if the cancer 
has not deeply invaded into the cancellous bone, and if a 
resection margin is obtainable. Segmental mandibulecto-
my should be performed for patients with extensive 
bone invasion (strong recommendation, high-quality evi-
dence).
(B)  Segmental mandibulectomy can be considered for those 
with an irradiated or edentulous thin mandible (weak 
recommendation, low-quality evidence).
While it is generally accepted that surgery should be performed 
to treat patients with obvious mandibular invasion, the extent of 
mandibular resection required is not always clear. Most surgeons 
may agree that marginal mandibulectomy is the best choice to 
preserve mandibular contour and function when the tumor en-
croaches or superficially invades the cortex, unless the cancel-
lous bone is extensively invaded. However, for cases in which 
the medullary bone is definitely involved, the decision is more 
problematic, and such cases may be subjected to segmental re-
section; despite subsequent severe morbidities, segmental resec-
tion may help in avoiding positive margins associated with mar-
ginal mandibulectomy.
Petrovic et al. [133] reported the results of marginal mandibu-
lectomy with a large number (n=362) of patients with oral can-
cer and demonstrated that microscopic bone involvement was 
identified in 15% of patients; positive bony margins were signif-
icantly associated with medullary bone invasion, primary sites 
of FOM and buccal mucosa, and with positive soft tissue mar-
gins after marginal mandibulectomy. But the locoregional recur-
rence-free and cancer-specific survivals were similar in patients 
without or with bone invasion, and local disease control rates 
were not different between patients with microscopically posi-
tive versus negative bone margins. A recent systematic review 
concluded that a marginal mandibulectomy would be an appro-
priate choice for oral cancers adherent to or superficially invad-
ing the cortex of mandible, since no statistically significant dif-
ference in 2- and 5-year local control rates and survivals was 
found between marginal and segmental resections in a meta-
analyses [149]. 
However, a segmental mandibulectomy is required to obtain 
the oncological safety margins of soft tissue in patients with ex-
tensive medullary invasion. If the inferior alveolar nerve canal is 
involved, a segmental mandibulectomy beyond the mandibular 
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and mental foramen is needed. It has been generally accepted 
that once the inferior alveolar canal is destroyed by invasive tu-
mors, anterior and posterior perineural extension takes place in 
both the edentulous and the dentate mandible. Thus, segmental 
mandibulectomy would be a better choice for these patients 
[150]. In addition, cases with previous irradiation to the mandi-
ble require further attention. Wax et al. [151] reported that irra-
diation may alter the bone’s resistance to tumor spread and in-
sisted that a segmental mandibulectomy is indicated for such 
cases. In addition, they opposed a marginal resection in the 
edentulous or in a previously irradiated mandible because of 
the risk of bony fracture or of osteoradionecrosis. 
On the other hand, other researchers have reported that there 
was no statistically significant difference between marginal and 
segmental mandibulectomies in the rate of positive margins; the 
survival rate was found to be significantly related to positive soft 
tissue margins, and not to bone invasion or the type of mandib-
ulectomy. The authors suggested that local recurrence is usually 
a result of positive soft tissue margins and does not correlate 
with the type of mandibulectomy [152]. Wolff et al. [153] also 
suggested that mandible-sparing surgery is oncologically safe in 
cases where the primary tumor does not erode the mandible 
even though in adjacency or where there is no indication of 
bone destruction. Accordingly, it would be relevant to evaluate 
whether a safety margin must be acquired in mandibulectomy 
despite the lack of benefit on disease control or survival, consid-
ering that segmental resection compromises the patient’s quality 
of life. Therefore, it could be concluded that marginal mandibu-
lectomy is an oncologically sound procedure if the tumor is not 
compromising soft tissue margins, when there is no radiographic 
evidence of extensive medullary or bony canal involvement in 
oral cancers. However, the final decision of the method of man-




(A)  Macroscopic and palpable margins including deep mar-
gin should be at least 10 mm from the tumor for FOM 
cancer (strong recommendation, moderate-quality evi-
dence).
(B)  Submandibular ducts and/or sublingual glands may be 
sacrificed (weak recommendation, low-quality evidence).
In FOM cancer, like in cancers of other sub-sites of the oral cav-
ity, the most important thing is to resect the tumor with an ap-
propriate margin considering anatomy. Generally, “margin” re-
fers to the distance from the tumor edge to the cut edge of the 
specimen. Histopathologically, a margin greater than 5 mm is 
designated as a “clear margin.” A margin less than 5 mm is con-
sidered to be a “closed margin,” and that less than 1 mm is de-
fined as an “involved margin” [154]. The optimal resection mar-
gin of oral cavity cancer to achieve clear margins histopathologi-
cally is still a controversial issue. It is well known that shrinkage 
of tissue occurs during tissue processing like fixation, embed-
ding, cutting, and mounting [155,156]. Because of tissue shrink-
age in oral cavity cancer, the pathological margins are much 
smaller than the preresection margins [113]. The extent of tissue 
shrinkage is variable depending on the type and site of cancer 
[157-159]. In a previous report by Johnson et al. [160], the 
postresection tissue shrinkage or contracture values were 24.8% 
and 20.9% for the mucosa and tongue, respectively. Contrac-
ture of 41% to 47.5% were reported for a lip specimen by Ege-
men et al. [161]. Considering the pathologic clear margin and 
tissue shrinkage values, the clinical resection margins should be 
at least 10 mm in oral cancer including FOM cancer. 
In FOM cancer, a macroscopic and palpable margin including 
a deep margin should be at least 10 mm. However, considering 
anatomical features like a mandible near the tumor, it may be 
difficult to resect the tumor with an appropriate margin. In such 
cases, widest margins are indicated, if possible. In the case of tu-
mors involving FOM that show abutment or invasion of the 
mandibular periosteum, it is necessary to consider marginal or 
segmental mandibulectomy to obtain adequate margins [142, 
162]. Additionally, sublingual glands and/or submandibular ducts 
may be sacrificed when they are included in the deep resection 
margins [163,164]. Sublingual lymph nodes may also be re-
moved with the sublingual glands in cases of sublingual lymph 
node metastasis [165,166].
C6. Buccal mucosa cancer 
Recommendation 19
(A)  For buccal cancer within the sumucosal layer, sufficient 
deep resection margins should be achieved by composite 
resection including the buccinators (strong recommenda-
tion, moderate-quality evidence). 
(B)  If the tumor invades the buccinator muscles, ideally, sur-
gical resection may be extended to the fat pads of the 
buccal space (strong recommendation, moderate-quality 
evidence).
(C)  If the tumor penetrates or involves to the skin, resection 
of 1 to 2 cm of normal skin around the tumor is required 
(strong recommendation, moderate-quality evidence).
The rate of local recurrence in SCC of the buccal mucosa is rela-
tively high because there is no anatomical barrier to spread in 
the buccal space [167,168]. The buccinator muscle and its over-
lying fascia are the only barriers preventing the spread of buccal 
cancer. Once the tumor penetrates beyond the buccinator mus-
cle and s encroaches on the buccal fat, there is no solid anatomic 
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barrier to limit the spread [169]. There is no consensus on the is-
sue of including the buccinator in the primary surgical resection 
specimen of a tumor within the submucosal layer. Ota et al. 
[170] proposed a surgical resection classification method based 
on the presence or absence of buccinator invasion. They recom-
mended that when the tumor was confined within submucosal 
layer, the buccinator muscle was to be spared, and if the tumor 
extended to the buccinator, the tumor was to be resected to in-
clude the buccinator muscle with the overlying fascia. They re-
ported a 73.7% disease-specific survival rate and an 89.5% lo-
cal control rate during treatment based on this classification. 
However, others argue that sufficient deep resection margins in-
cluding the buccinator should be resected together even if the 
tumor is confined within the submucosal layer [171]. Surgical 
margin status is an important prognosticator in oral SCC. Stud-
ies have shown that exclusive reliance on surgical margins on 
the tumor bed is strongly associated with local control. The pri-
mary aim of surgical resection is to achieve a microscopically 
complete surgical resection at the time of initial surgery [172-
175]. Oral cancer frequently shows microscopic spread beyond 
gross resection margins, which alters the margin status [175, 
176]. Intraoperative frozen section could help in assessing the 
margin status, but some may argue that frozen sections do not 
alter surgical margin status [177-179]. Narrow band imaging 
may be a useful adjunctive technique for acquiring free resec-
tion margins, but further research is required regarding this as-
pect [180,181]. In the minimum, a resection margin of more 
than 5 mm is now acceptable in oral SCC [125,182]. Given this, 
en bloc resection including the buccinator with its overlying fas-
cia even for tumors confined within the submucosal layer has 
potential benefit to achieve clear deep resection margins. If the 
tumor invades the buccinator muscles, the optimal surgical re-
section may be extended to the fat pads of the buccal space. 
The issue of resection of the overlying skin along with tumor 
should be considered carefully. Skin resection may result in fa-
cial and mastication defects. Liao et al. [183] reported that addi-
tional skin resection may not impact OS. Therefore, if enough 
surgical resection margin (>10 mm) is secured, it is better to 
preserve the overlying skin. Preoperative CT/MRI is helpful to 
decide on additional skin resection. If the distance between the 
overlying skin and deep resection margin is more than 13 mm 
(skin thickness, 3 mm), the skin may be preserved. If the tumor 
is either invading towards or involving the skin, resection of 1 to 
2 cm of normal skin around the tumor is required [183]. In cas-
es of T4b buccal cancers with invasion to the masticator space 
(posterolateral extension), en bloc removal of all soft-tissues in 
the masticator space is advocated to safely remove tumor con-
tained within the masticator compartment. This compartment 
surgery provides an opportunity to acquire safe margin for can-
cers actually invading into the masticator space. In general, it is 
not appropriate to club all patients with masticator space in-
volvement into one group [184]. 
C7. RMT cancer 
Recommendation 20
(A)  RMT cancer frequently invades to the mandible and is 
underestimated. Careful preoperative evaluation should 
be made regarding adjacent bone invasion, because of 
the limited space between the mucosa and the mandible 
(strong recommendation, moderate-quality evidence).
(B)  Trismus-releasing procedures including coronoidectomy 
and myotomy of the masticator muscles may be consid-
ered simultaneously for patients undergoing mandibulec-
tomy (weak recommendation, low-quality evidence).
In many cases of SCC of RMT, the invasion of the mandible is 
an important factor for decisions regarding dissection extent. 
Cancer clinically localized to superficial layers of the RMT is 
rare, and tumors in most cases penetrate into the submucosal 
layer and invade into the mandible. The mandible located poste-
rior to the third molar has a large surface with abundant pores 
on the cortex, which makes it easy to infiltrate the marrow as 
well as the cortex. When the tumor reaches the marrow, it may 
progress horizontally through the inferior alveolar canals and 
nerves. The incidence of pathologically-proven mandibular in-
volvement in surgical specimens was reported to be about 
12%–53% [185-188]. 
Because invasion of the inferior alveolar nerve occurs after 
invasion of the inferior alveolar canal, this nerve could be 
spared in cases with a grossly intact inferior alveolar canal. But 
if the inferior alveolar canals are invaded, sufficient resection in-
cluding the inferior alveolar nerve should be performed, due to 
the possibility of perineural spread [189]. If there is inadequate 
amount of normal tissue between the mandible and the tumor, 
the surgeon should consider including part of the mandible in 
the resection extent [190]. 
Trismus refers to the restriction of opening of the mouth. Cur-
rently, an interincisal distance of 35 mm or less is the accepted 
cutoff point for trismus [191]. Patients with trismus show com-
promised oral hygiene, swallowing, and conversation, which se-
verely impacts quality of life [192-194]. Studies show that 
55%–80% of oral cancer patients have preoperative or postop-
erative trismus [195-197]. Advanced T stages and postoperative 
RT are associated with the development of trismus after surgery 
[197,198]. 
The recommendations for simultaneous trismus-releasing pro-
cedures including myotomy of masticator muscles and coro-
noidectomy during resection are unclear because of lack of suf-
ficient evidence. The potential benefit of these additional proce-
dures is that these procedures may help avoid revision surgery 
requiring general anesthesia. Fibrosis of the surgical field needs 
to destruct greater tissue destruction to achieve the purpose. The 
potential risk of these procedures includes increase in the oper-
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ating time, which may result in surgical complications. However, 
these procedures may concomitantly be performed for patients 
undergoing wide excision including marginal mandibulectomy 
with acceptable increase in surgery time (less than 1 hour) and 
surgical complications [197]. 
C8.  Neck management for oral cancer 
What is the appropriate strategy for the management of 
cervical lymph nodes in oral cancer?
C8-1.  Management for clinically negative neck (N–) in patients with 
oral cancer 
Recommendation 21
(A)  ND can be considered in T2–4 oral cancer (weak recom-
mendation, low-quality evidence).
(B)  DOI can be used as a predictive parameter of neck me-
tastasis for ND of oral cancer (strong recommendation, 
moderate-quality evidence).
Because of the variety of subsites in the oral cavity, it is difficult 
to uniformly categorize patients with oral cancer for elective 
neck dissection (END). Rates of regional metastatic spread differ 
by subsites, and sufficient evidence is lacking for making recom-
mendations on END in early stage cancer for most of the sub-
sites excluding the oral tongue and FOM. The tongue is a well-
studied subsite of the oral cavity for SCC. Although several 
studies reported that early-stage tongue carcinomas have higher 
rates of metastatic spread than do FOM carcinomas, there is 
limited comparison with other oral cavity subsites [199,200]. 
In several studies on END in early oral cancer, the probability 
of occult nodal disease based on the clinical T stage was estimat-
ed [201,202]. It is difficult to estimate the prevalence of occult 
nodal metastasis due to differences in patient populations, sub-
site distributions, extent of dissection, and the method of histo-
logic node analysis between these studies. In the END series, in 
which elective neck treatment was universally applied, the prev-
alence of occult positive nodes was between 6% and 25% for 
T1 oral cancer and 20% to 32% for T2 oral cancer. When stud-
ies comparing observation and ND were included, the preva-
lence of occult node disease in early oral cancer approached 
40% to 50%, but these numbers can be inflated due to the se-
lection bias of clinical parameters associated with a higher 
chance of occult neck metastasis [203-206]. These data should 
be interpreted carefully because there is insufficient high-quality 
evidence surrounding 20% of the treatment threshold for END 
determination [203]. However, it can be proposed that most 
cases with oral cancer higher than T2 should be candidates for 
END.
The DOI of the primary tumor was reported to have a signifi-
cant effect on the spread of occult node, particularly in the case 
of oral tongue cancer. A DOI greater than 4 mm is associated 
with an increased risk of occult node metastasis [207]. In the 
multivariate analysis, only the DOI predicted cervical node me-
tastases with a relative risk ratio of 9.4 (95% confidence interval 
[CI], 1.5 to 57.7) for lesions 4 mm or greater thickness [201]. An 
additional retrospective study showed a relationship between 
increased tumor thickness and an increased risk of occult node 
metastasis [208]. The significance of more than 4 mm of tumor 
depth was identified as an important predictor of occult node 
metastasis in the RCT, which assessed END relative to observa-
tions for early oral cancer [205,209]. Future studies have shown 
similar trends in early oral cancer compared to resection alone 
and resection with selective ND (level I–III). Researchers ob-
served an increase in occult node metastasis for tumors with a 
depth of 4 mm or more.
Because of these findings, we recommend END when the 
DOI exceeds 4 mm. Recently, the newly revised AJCC staging 
system reported that tumors with a DOI of over 5 mm are now 
categorized into T2. Considering this T stage criterion for END, 
the cutoff value of DOI can be modified with the surgeon’s ex-
perience. However, the biggest limitation on the use of DOI cut-
offs is that it is difficult to obtain this information before it is 
necessary. 
C8-2. Extent of ND for clinically negative neck (N–) in oral cancer
Recommendation 22
(A)  Selective ND (level I–III) can be applied as END in oral 
cancer (weak recommendation, moderate-quality evi-
dence).
(B)  Level IIb can be omitted in END in oral cancer (strong 
recommendation, high-quality evidence).
(C)  Perivascular lymph node dissection should be included 
in END in oral cancer (strong recommendation, moder-
ate-quality evidence).
When the surgeon decides to perform END on patients with N0 
oral cancer, it is important to decide the extent of surgery. Sev-
eral studies have compared selective ND (level I–III) and modi-
fied radical ND. 
Previous reports showed that OS did not differ among pa-
tients with selective ND (level I–III) and modified radical ND, 
and therefore selective ND (level I–III) can be considered as the 
standard elective treatment for oral cancer [210]. Other studies 
have also reported that selective ND (level I–III) has been iden-
tified as an appropriate staging procedure to provide valuable 
pathologic cervical node information for patients with oral can-
cer [211-213]. Byers [214] reported that Level III lymph nodes 
were observed in five cases without involvement in level I and/
or II in the modified radical ND of oral cancer. Also, two out of 
76 people had positive nodes at level IV without involvement of 
the upper lymph nodes. 
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In the last 20 years, quality of life has been assessed as an es-
sential secondary outcome along with survival rates. Thus, an 
assessment of the quality of life for oral cancer patients has be-
come an important aspect of postoperative care and even a tar-
get of therapeutic approaches [215]. Selective ND (level I–III) 
are associated with lower rates of complications and faster re-
covery [216]. Therefore, due to the minor morbidity associated 
with high efficiency, a selective ND (level I–III) is recommended 
as a definitive therapeutic approach in N0 oral cancer.
In terms of level IIb lymph node metastasis, there have been 
two meta-analysis studies. One study found that level IIb had a 
low rate of metastasis (6%) and little isolated level IIb metasta-
ses was found [217]. Therefore, it was suggested that level IIb 
lymph nodes need not always be dissected in oral cancer pa-
tients. Another meta-analysis reported that the nodal metastasis 
rate to level IIb in previously untreated oral cancer was 6.0% 
(95% CI, 3.5 to 8.6) [218]. Pantvaidya et al. [219] found that 
level IIb metastases were associated with level IIa metastases in 
68.1% of ND, while only 11.3% of all level IIa metastases had 
positive nodes at level IIb. Bhattacharya et al. [220] also report-
ed that the positive nodes of level IIa were always observed in 
patients with a positive level IIb nodes. Therefore, we propose 
that the assessment of level IIa should be performed during ND, 
and that level IIb dissection is unnecessary if there is no suspi-
cious lymph node at level IIa.
The perivascular lymph node is one of the subunits of the lev-
el Ib. These perivascular lymph nodes may be the major meta-
static reservoirs in oral cancer [221]. Lim et al. [222] studied 
tongue cancer and FOM cancer patients with N0, and conclud-
ed that four out of 72 with tongue cancer and two out of 27 
FOM cancers had perivascular lymph nodes. Agarwal et al. [223] 
analyzed oral cancer with N0 and reported that 19 (8.22%) of 
the 231 cases were found to have isolated perivascular nodal 
metastasis. 
C8-3.  Sentinel node biopsy for clinically negative neck (N–) in oral 
cancer
Recommendation 23
Sentinel node biopsy can be an alternative to selective ND 
(weak recommendation, low-quality evidence).
Increased evidence of the effects of sentinel node biopsies on 
early stage oral cancer has been released over the past decade. 
A meta-analysis of the available studies on a total of 301 pa-
tients with oral cancer showed that the sensitivity of sentinel 
node biopsy ranged from 0.75 to 1, and pooled sensitivity using 
the random effects model was 0.926 (95% CI, 0.852 to 0.964) 
[224]. Since that time, results of the American College of Sur-
geons Oncology Group examined the accuracy of sentinel node 
biopsy in 140 patients of oral cancer in the early-stage (T1–
T2N0) [225]. Results revealed a 94%-negative predictive value 
with routine hematoxylin and eosin stain, while the value im-
proved to 96% with additional sectioning of the sentinel node 
and immunohistochemical analysis. In addition, improved per-
formance was noted for T1 vs. T2 lesions (negative predictive 
value, 100% vs. 94%), and for experienced (in sentinel node 
biopsy) versus novice surgeons (negative predictive value, 100% 
vs. 95%). 
In principle, the sentinel node biopsy should be associated 
with a reduced morbidity rate compared to END, but the data 
supporting this contention for oral cancer is sparse [226]. In a 
study comparing outcomes after sentinel node biopsy and END, 
authors reported that there were no differences in the European 
Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire Core 30 (EORTC QLQ-30) [227]. Overall, 
the evidence so far suggests that for experienced clinicians, the 
sentinel node biopsy is a reliable method for staging N0 necks 
to early oral cancer patients. However, there is a lack of conclu-
sive data showing a reduction in morbidity compared to END.
C8-4.  Management of clinically positive neck (N+) in patients with oral 
cancer
Recommendation 24
(A)  Therapeutic ND should be performed for N+ in patients 
with oral cancer. The extent of ND should include at least 
level I, II, and III (strong recommendation, low-quality 
evidence). 
(B)  Elective contralateral ND is not routinely recommended 
for ipsilateral N+ oral cancer (weak-recommendation, 
low-quality evidence).
Cervical lymph node metastasis has been identified as one of 
the most important prognostic factors for patients with oral can-
cer [228,229]. Metastasis to the lymph node occurs in about half 
of the oral cancer patients at the initial stage of diagnosis [230]. 
It has been found that lymph node metastasis predicates a 50% 
decrease in survival rates [231]. Moreover, recent studies have 
shown that a higher lymph node density was associated with a 
worse survival rate [232,233]. Eliminating the metastatic lymph 
node is one of the most important procedures in oral cancer pa-
tients who have positive lymph nodes. 
Treatment of metastatic lymph nodes should be performed 
according to the involved level of clinically positive neck nodes. 
Comprehensive ND such as radical or modified radical ND 
should be considered according to the status of lymph nodes 
metastasis [234]. Recently, several studies have reported that se-
lective ND performed in a select group of patients with positive 
lymph nodes resulted in excellent regional control. The key 
learning from these trials is that cervical lymph node metastasis 
occurs in a predictive pattern. According to a study by Shah et 
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al. [235], ipsilateral levels I, II, and III are the most frequently in-
volved sites in cervical metastasis of advanced oral cancers. Lev-
els IV (4.7%) and V (3.8%) are rarely involved in oral cancers 
[219,236]. However, several factors such as advanced T stage, 
multiple clinically positive nodes, and extracapsular spread were 
associated with neck failure in patients treated with selective 
ND due to metastasis to level IV and V, or due to higher region-
al recurrence rates [237-241]. Therefore, dissection of neck at 
level IV or V should be added to a dissection of level I, II, and III 
according to the individual patient status.
Several studies have evaluated the effect of contralateral ND 
for ipsilateral N+ oral cancer. According to a report, the occult 
rate of contralateral lymph node metastasis was 11% [242]. The 
occult rate dropped to 2.9% when primary tumors close to the 
midline were excluded [243]. Contralateral lymph node metas-
tasis was associated with multiple positive nodes (two or more) 
rather than with a single positive node [244], and with level IV/
V involvement rather than with other level involvement [245]. 
Oral cancers are associated with a low incidence of contralateral 
metastases; therefore, contralateral ND my not be routinely 
considered.
C9.  Reconstruction for oral cancer defects 
What are the appropriate reconstruction methods for oral 
cancer defects?
C9-1. Soft tissue reconstruction for oral cancer defects
Recommendation 25
(A)  Flap reconstruction is recommended to preserve ade-
quate speech and swallowing in patients with consider-
able defects after oral cancer surgery (strong recommen-
dation, moderate-quality evidence).
(B)  Flap reconstruction is recommended for the partial glos-
sectomy defect approaching half of the tongue or more, 
to provide better swallowing function (strong recommen-
dation, low-quality evidence).
(C)  Flap reconstruction and postoperative rehabilitation 
should be performed for patients who underwent subto-
tal or total glossectomy to preserve functional speech 
and swallowing (strong recommendation, low-quality 
evidence).
(D)  Flap reconstruction is recommended for FOM defects to 
prevent communication between neck and oral cavity 
and to preserve mobility of the tongue for adequate 
speech and swallowing (strong recommendation, low-
quality evidence).
(E)  Flap reconstruction is recommended for considerable 
buccal defects to preserve mouth-opening ability and for 
structural cosmesis (weak recommendation, low-quality 
evidence).
(F)  The radial forearm and the anterolateral thigh free flaps 
are the preferred reconstructive methods for oral soft tis-
sue defects while other types of reconstructive surgery 
may be performed depending upon the extent of primary 
(F)  The radial forearm and the anterolateral thigh free flaps 
are the preferred reconstructive methods for oral soft tis-
sue defects while other types of reconstructive surgery 
may be performed depending upon the extent of primary 
resection, patient’s morbidity, and surgeon’s preference 
(strong recommendation, low-quality evidence).
Reconstructive surgery is important in the multidisciplinary 
management of oral cancer; this surgery is usually determined 
based on the location and extent of surgical resection. Patient 
morbidity and survival could be critically influenced by the 
quality of reconstruction. Microvascular free flap is the primarily 
recommended reconstructive method for most of the oral soft 
tissue defects that need tissue transfer, while local or regional 
flap methods may be indicated in specific situations [246]. Al-
though many studies have investigated functional outcomes fol-
lowing treatment of oral soft tissue reconstruction, high-quality 
level I evidence is still lacking due to a limitation of the stan-
dardized approach, pertaining to functional assessment [247]. To 
date, there have been several systematic reviews and prospec-
tive cohort studies that have addressed these issues. 
Oral soft tissues include tongue, FOM, buccal mucosa, and the 
retro-molar trigone. The objectives of soft tissue flap reconstruc-
tion for tongue defects after tumor resection are to preserve 
mobility of the residual tongue and to restore tongue bulk for 
proper speech and swallowing functions [248]. Flap reconstruc-
tion is usually required if more than 50% of the tongue is re-
sected [247]. There are two retrospective case-control studies di-
rectly comparing the functional outcomes between free flap re-
constructions and primary closure after hemiglossectomy 
[249,250]. In terms of swallowing, better functional outcomes 
were reported in patients with flap reconstruction compared to 
those with primary closure following hemiglossectomy of the 
oral tongue, while speech intelligibility appeared to be not supe-
rior in the flap reconstruction group as compared to the primary 
closure group [249,250]. However, the above mentioned studies 
were retrospective case-control studies with small sample sizes; 
thus the level of evidence is low. Uwiera et al. [251] prospec-
tively evaluated functional outcomes after hemiglossectomy 
with bilobed radial forearm free flap reconstruction, and report-
ed functional speech and excellent swallowing outcomes. A re-
cent prospective study indicated that the preservation of the tip 
of the tongue is important for speech outcomes [252]. However, 
additional well-designed prospective studies are indicated [247]. 
Although current data generally support the use of flap recon-
struction for hemiglossectomy defects, whether flap reconstruc-
tion is helpful for partial glossectomy defects involving less than 
1/2 of the anterior tongue is controversial, and there is a lack of 
adequate evidence. Alternative reconstructive options including 
primary closure, secondary intention, skin grafts, and skin graft 
substitutes (e.g., AlloDerm) may also provide relatively good func-
tional outcomes for defects involving less than 1/2 of the mobile 
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tongue. For defects involving less than 1/3 of the mobile tongue, 
soft tissue flap reconstruction is not usually recommended.
For reconstruction of subtotal or total glossectomy, a bulkier 
flap is required to reconstruct the greater volume of the resec-
tion, and flaps such as the anterolateral thigh are commonly 
used [253]. Because it is quite evident that soft tissue flap recon-
struction is required for subtotal or total glossectomy defects, 
there is no study that directly compares functional results be-
tween flap reconstruction and primary closure/secondary heal-
ing. Recent systematic reviews have indicated relatively favor-
able swallowing outcomes, and report that 82% to 97% of pa-
tients resumed oral feeding at 1 year after flap reconstruction 
for subtotal or total glossectomy defects [254,255]. Also, pa-
tients who attended postoperative swallowing and speech reha-
bilitation sessions demonstrated superior functional outcomes 
and improved quality of life scores [254-256]. 
The purpose of the FOM reconstruction is to close defects 
communicating with the neck to prevent blood vessel rupture 
due to salivary contamination [253]. Appropriate flap width is 
required not to tie the tip of the tongue to the FOM. Fasciocuta-
neous radial forearm free flaps are popular reconstructive op-
tions for FOM defects. Recently, pedicled flaps such as facial ar-
tery musculomucosal flaps have been increasingly used for small 
or modest defects of the FOM, providing excellent functional 
and aesthetic outcomes [257].
The goal of buccal defect reconstruction is to prevent limita-
tion of mouth-opening or even trismus, and to preserve struc-
tural cosmesis [253,258]. If muscle loss is noticeable or buccal 
defect is observed after resection of a T2 tumor or more, soft tis-
sue flap reconstruction is recommended, while skin graft is 
mainly performed for superficial defects of the buccal mucosa 
[259]. The radial forearm fasciocutaneous flap is a preferable re-
constructive option for buccal mucosal defects as it was shown 
to achieve excellent functional outcomes in preserving the origi-
nal open-mouth width [258,260]. For reconstruction of through-
and-through buccal defects, folded fasciocutaneous free flaps or 
flaps with dual perforating skin paddles should be used to re-
store oral functions as well as to maintain acceptable cosmetic 
outcomes [261,262]. 
 
C9-2. Mandibular reconstruction for oral cancer defects
Recommendation 26
(A)  The osteocutaneous free flap, especially the fibular free 
flap, is regarded as the primary method of mandibular 
reconstruction (weak recommendation, low-quality evi-
dence).
(B)  Mandibular reconstruction using computer-aided design 
(CAD) and manufacturing (CAM) can be considered for 
reducing trial and error and surgical time (weak recom-
mendation, low-quality evidence).
Reconstruction is difficult but inevitable for functional and cos-
metic outcomes in cases which result in mandibular defects due 
to treatment of oral malignancies, especially in those cases in-
cluding the condyle. For the planning of mandibular reconstruc-
tion, a generally accepted classification of the mandibular defect 
could guide further understanding of the optimal options for re-
construction. However, the choice of reconstruction has been 
usually based on the individual surgeon’s preference of or expe-
rience with a particular option. Therefore, it will be necessary to 
establish a standardized classification of the size and types of 
defects not only describing the pictorial records of the defect 
but also demonstrating the different complexities of defects, 
while suggesting the best methods of reconstruction. 
Brown et al. [263] recently suggested a new classification sys-
tem for mandibular defects after oral cancer surgery. They ana-
lyzed 49 studies of mandibular defects and consequently pro-
posed a new classification based on the four corners of the man-
dible (two angles and two canines) with further subclasses (Ic, 
IIc, and IVc) contingent on the condylectomy. They also demon-
strated that the increasing defect class was related to the size of 
the defect, osteotomy rate, and functional and aesthetic out-
comes, and accordingly insisted that this system could guide 
method selection for mandibular reconstruction.
The mandible is important for speech, deglutition, mastica-
tion, and lower face shape, and the goals of mandibular recon-
struction are restoration of form and function while considering 
impact on quality of life of the patient. Mandibular defects after 
oral cancer surgery usually involve the skin, mucosa, nerve, or a 
combination of these; hence, the plans for restoration of form 
involve various combinations of these tissues. When planning 
autologous bone grafting, it is necessary to choose the area that 
matches with the thickness and angulation of the mandible; at 
the same time, the donor site morbidity should also be consid-
ered based on the patient’s individual condition including vascu-
lar status. Dentition can be predictably restored using osseointe-
grated implants, consequently improving mastication and other 
functions. Soft tissue including the oral mucosa and/or skin re-
placements need to be thin and pliable enough so as not to in-
hibit the mobility of the remaining oral structures in terms of 
functional recovery.
The osteocutaneous free flap is considered the main method 
for the primary method of mandibular reconstruction, because 
it has consistently provided the best functional and aesthetic re-
sults in patients. This technique, performed simultaneously with 
cancer ablation, is the fastest surgery for patients and provides 
the most successful rehabilitation [264]. The advantages and dis-
advantages of the currently well-known osteocutaneous free-
flap options for mandibular defects are summarized in Table 6. 
Moubayed et al. [265] recently reviewed the frequency of use of 
osteocutaneous free flaps for mandibular reconstruction and re-
ported on a preliminary comparison of quality of life according 
to the flap methods used. In their analyses, the fibular free flap 
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(72.6%) was the most frequently used mandibular reconstruc-
tion method followed by the radial forearm (14.9%), iliac crest 
(8.4%) and the subscapular system free flaps (3.7%). They also 
showed a trend towards better quality of life and depression al-
leviation in the fibula free flap group; however, these findings 
did not reach statistical significance because of heterogeneity in 
patient age, follow-up times, and defect types, and thus cannot 
be used to draw firm conclusions. Another study by Zavalishina 
et al. [266] about the patients’ quality of life after mandibular 
resection and reconstruction with the free fibula flap demon-
strated that most patients reported satisfaction with their overall 
quality of life. 
Although vascularized bone grafting is the preferred method 
of mandibular reconstruction, this technique can increase surgi-
cal time and blood loss, which may be associated with increased 
morbidity and mortality. Bridging plates can be used to select 
segmental mandibular reconstruction. Okura et al. [267] in-
spected the plate survival and factors influencing the occurrence 
of complications, and reported a 5-year plate survival rate with 
no complications of 62.2%; anterolateral defects and preopera-
tive RT were identified as independent risk factors for plate sur-
vival. They concluded that the use of bridging plates may be an 
option for lateral mandibular reconstruction in cases without 
previous irradiation. Relatively short mandibular defects with 
sufficient vascularity could possibly be treated with particulate 
cancellous bone marrow combined with a titanium mesh 
(PCBM-MESH). Miyamoto et al. [268] introduced the use of the 
PCBM-MESH for mandibular reconstruction and demonstrated 
a 90% (nine of 10 patients) success rate; they suggested PCBM-
MESH as an attractive reconstruction option, if sufficient alveo-
lar ridge with good oral membrane. However, this is in sharp 
contrast to the use of alloplastic supports of nonvascularized 
cancellous bone grafts wrapped in pedicled musculocutaneous 
flaps [264].
It is often accepted that reconstruction with composite free 
flaps promises better functional and aesthetic outcomes than 
does bridging the paucity with reconstruction plates. van Ge-
mert et al. [269] compared health-related quality of life using 
the EORTC questionnaires in patients who received free fibula 
flaps versus reconstruction plates after segmental mandibulecto-
my on the lateral mandible. They demonstrated that reconstruc-
tion with a fibula free flap did not offer obvious further benefit 
on quality of life compared to bridging plates. The authors con-
cluded that plate reconstruction with sufficient soft tissue re-
mains a suitable technique for the reconstruction of segmental 
defects of the lateral mandible, unless dental rehabilitation using 
implants would be expected in the fibula free flap. 
Besides bone grafting, transport disk distraction osteogenesis 
is an alternative method that can be applied for the reconstruc-
tion of lateral mandibular defects after oral cancer surgery 
[270,271]. Furthermore, the recent introduction of a three-di-
mensional CAD software and additive manufacturing technolo-
gy can enable patient-specific scaffold and matrix manufactur-
ing; this includes biocompatible patient-specific scaffolds and 
matrices, osteogenic cells, and osteoinductive and angioinduc-
tive growth factors [272]. Studies evaluating the efficacy and va-
lidity of these new tissue engineering technologies are currently 
ongoing. 
In the past, the utility of an osteocutaneous free flap during 
mandibular reconstruction greatly depended on the surgeon’s 
expertise and decision-making. To overcome this problem, com-
puter-aided surgery was introduced in the late 2000s, and has 
been applied to the reconstruction of segmental mandibular de-
fects that occur after oral cancer surgery. Computer-aided surgi-
cal technology includes virtual surgical planning, CAD, CAM, 
rapid prototyping, and intraoperative navigation-assists in the 
planning of reconstructive surgery.
Reconstruction using CAD/CAM proceeds through four phas-
es: planning, modeling, surgery, and evaluation. This technique 
can surmount a number of trial-and-error issues which may 
happen in the surgical field and may also reduce operating time. 
Traditional methods (i.e., intraoperative planning), involve re-
peated trial and error, and require significant time investment in 
perfecting procedures such as those for the alignment of the 
folded angle of the reconstruction plate. Since CAD/CAM facili-
tates the performance of these tasks using a stereolithographic 
model, this method significantly lowers ischemic and operating 
time. According to a literature review, the accuracy of intraoper-
ative CAD/CAM use and subsequent plate designing reached 
92%, and this technique was efficacious in elevating the accura-
cy of dental occlusion and the orthognathic relationship [273, 
274]. Furthermore, the stereolithographic model-assisted recon-
struction is also useful in the rebuilding of the mandibular con-
dyle with a fibular free flap with satisfactory esthetical and func-
tional outcomes [275].
However, the most important limitation of CAD/CAM in oral 
cancer surgery is that it does not allow for an exact estimation 
of the tumor margin in the mandible. Therefore, surgeons should 
consider the likelihood that in the operating room, more tissue 
will be sacrificed than planned. There are reports that the likeli-
hood of achieving a negative resection margin when performing 
tumor surgery using CAD/CAM is only about 5% [276,277]. 
Table 6. Advantages and disadvantages of the osteocutaneous free 
flaps for mandibular reconstruction
Parameter Fibula Radial forearm Iliac crest Scapula
Bone length (cm) Up to 25 Up to 12 Up to 15 Up to 20
Skin paddle 2 1 1 2
Pedicle length Short Very long Short Long
Dental restoration Possible Impossible Best Limited
Donor site morbidity Minimal Fracture LOM LOM
Two-team approach Possible Possible Possible Limited
Quality of life Best Intermediate NA Worst
LOM, limitation of motion; NA, not assessable.
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Additionally, recipient vessels, pedicle length, oral alignment 
and overlying dermal amount, location and type of perforating 
vessels supplying the osteocutaneous fibula flap skin paddle, 
and volumetric restoration in mandible reconstruction are criti-
cal components; however, it is difficult to evaluate and apply 
these variables in the CAD/CAM system [274]. Additionally, 
CAD/CAM use leads to higher operating time; thus, taking into 
account the risk of tumor progression during that time, patients 
are required to undergo surgery within a maximum of 3 weeks 
[274]. If the above mentioned problems are resolved, applica-
tions of CAD/CAM in mandibular reconstruction can be greatly 
extended in the future.
D.  Postoperative follow-up 
How can we postoperatively follow-up patients with oral 
cancer? 
D1. Long-term follow-up schedules 
Recommendation 27
(A)  Patients should be regularly examined for at least 5 years 
after treatment (strong recommendation, high-quality 
evidence).
(B)  Because of the high risk of locoregional recurrence, pa-
tients must be inspected frequently for the first 2 years; 
this schedule requires patients to be examined every 1 to 
3 months during year 1, and every 2 to 6 months during 
year 2 (strong recommendation, low-quality evidence).
Follow-up schedules for each patient should be devised individ-
ually. The survey of quality of life, nutritional status, speech and 
swallowing function, dental status, and investigation of compli-
cations after treatment including thyroid function, smoking and 
alcohol consumption habits, etc., should be examined periodi-
cally. There are several reasons to regard posttreatment follow-
up in patients with oral cancer as important, including the early 
identification of locoregional recurrence, monitoring and man-
agement of complications, optimization of rehabilitation, en-
couraging cessation of smoking and excessive alcohol consump-
tion, providing emotional support to patients and their families, 
and patient counseling and education. 
It is recommended that patients with oral cancer visit fre-
quently after treatment, especially during the first 2 years, since 
the risk of locoregional recurrence is high during this time. If 
there is no evidence of recurrence, the frequency of visits may 
be reduced later and follow-up measures should be completed 
by year 5. Patients with advanced stage of disease or specific tu-
mors, those who require continuous special rehabilitation, and 
those who need a longer period of follow-up may be examined 
for a longer time period, and maybe even for the rest of their 
lives [278-286]. The European Journal of Surgical Oncology rec-
ommends that the follow-up schedule in patients with head and 
neck cancer should include visits every 4 to 6 weeks during the 
first 2 years, every 3 months during year 3, twice yearly in year 
4 and 5, and then once every year [287]. Members of the Amer-
ican Society for Head and Neck Surgery reported a 73% of the 
agreements in their consensus report, in response to a schedule 
comprising monthly follow-up visits during the first year after 
surgical treatment, visits every 2 to 3 months during year 2, and 
visits every 4 to 6 months during years 3 to 5 [288]. Many stud-
ies have revealed that the follow-up protocol should be planned 
such that the first 2-year follow-up generally occurs between 
week 4 and week 8 postoperatively, and subsequent visits occur 
every 3 to 6 months [278-281]. 
D2. Tests during the follow-up period
Recommendation 28
(A)  To provide reference images, repeating pretreatment 
baseline imaging studies (CT or MRI) is recommended 
within 6 months after treatment (strong recommenda-
tion, low-quality evidence).
(B)  PET-CT is recommended for the detection of distant me-
tastasis, recurrence, and second primary tumors (strong 
recommendation, moderate-quality evidence).
(C)  A chest radiography or CT study is recommended for the 
detection of lung metastasis and second primary tumors 
in the lung (strong recommendation, moderate-quality 
evidence).
(D)  US can be considered for the detection of cervical lymph 
node recurrence (weak recommendation, low-quality 
evidence).
The first step of the follow-up protocol in patients with oral can-
cer should include a patient education program related to the 
potential symptoms and signs of recurrence. Tobacco smoking 
and alcohol cessation programs should also be included in these 
education sessions [278,289,290]. During the follow-up period, 
physical examination including laryngoscope or fiberscope ex-
amination should be conducted for oral cavity inspection, and 
the palpation of the primary site and the neck including cervical 
lymph nodes should be performed.
Baseline images of CT or MRI implemented between 3 to 6 
months after the surgical, radiological, or combined treatment 
for advanced oral cancer can be used for comparing with subse-
quent images for the early detection of abnormalities [291]. Pa-
tients with oral cancer require careful follow-up including thor-
ough clinical examinations and imaging studies at 3- to 4-month 
intervals for a period of 2 years after definitive treatment.
PET-CT exhibits superior performance for detecting recur-
rences or second primary malignancies. In addition, PET-CT has 
the advantage of allowing for a systemic evaluation; a sensitivity 
of up to 93% has been reported for this technique, for detecting 
128    Clinical and Experimental Otorhinolaryngology    Vol. 12, No. 2: 107-144, May 2019
recurrent oral cancer. PET-CT shows nearly 100% accuracy in 
diagnosing distant metastasis in cancer patients [292,293].
Chest radiography should be performed as a part of the rou-
tine protocol for head and neck cancer follow-up to detect lung 
metastasis and second primary malignancies in the lung. At 
times, it is more appropriate to use chest CT rather than chest 
radiography for evaluating patients with advanced oral cancer 
[294,295].
Several studies have evaluated the efficiency of US and physi-
cal examination including manual palpation during follow-up, 
and have revealed that US showed 97.5% accuracy in detecting 
lymph node enlargement. Other studies have also reported that 
US and US-guided fine needle aspiration cytology provide im-
portant information for detecting recurrence of cervical lymph 
node [294-298]. 
In patients who were treated with radiation therapy, CT, MRI, 
and US could not specifically differentiate postradiation edema 
from recurrence. Therefore, CT, MRI, or PET-CT should be per-
formed within 3 to 6 months after treatment to obtain reference 
image [293]. Although the optimal follow-up strategy after sur-
gical treatment still remains under debate, a careful clinical ex-
amination should be performed, if the results are positive, fol-
lowed by contrast CT [278]. PET-CT are applied to the screen 
for metastasis in patients undergoing surgery with RT or chemo-
radiotherapy (CRT) [293,299-301]. Patients treated with defini-
tive chemoradiation therapy should be evaluated with PET-CT 
at 3 months after the completion of therapy; the primary and 
neck disease should be assessed to evaluate treatment response 
and to plan salvage neck surgery if required [293,299-301]. Tu-
mor markers and gene expression profiling are known to be less 
sensitive and have low cost-effectiveness, are thus not recom-
mended as useful markers for the follow-up of oral cancer 
[302,303]. 
D3. Thyroid function evaluation
Recommendation 29
(A)  A thyroid function test is recommended to identify the 
presence of hypothyroidism in patients with oral cancer 
treated with RT in the head and neck area (strong rec-
ommendation, low-quality evidence).
(B)  Thyroid function should be examined twice yearly during 
the first 5 years after treatment, and annually thereafter. 
Periodic thyroid function tests may be conducted to fol-
low-up thyroid function for 10 years (weak recommenda-
tion, low-quality evidence).
At least 50% of patients who had undergone radiation therapy 
in the head and neck area were prone to hypothyroidism result-
ing in biochemical injury. Previous reports revealed that 10% to 
70% of patients suffer from thyroid dysfunction after head and 
neck cancer treatment [304-306]. Thyroid function is evaluated 
to measure the serum levels of thyroid stimulating hormone 
(TSH) and free thyroxine (fT4). 
Damaged vascular supply is one of the pathophysiologic 
causes of hypothyroidism. During neck lymphatic dissection, 
the vascularity around the thyroid gland may be iatrogenically 
damaged or intentionally sacrificed. These procedures distract 
the vascularities of the thyroid gland and eventually affect thy-
roid function. In addition, radiation-induced fibrosis may lead to 
decreased thyroid function not only due to impaired vascularity 
but also due to fibrosis of the entire gland. Increased TSH levels 
have been found in 20% to 25% of patients who have under-
gone radiation therapy in the head and neck area, and these pa-
tients have an increased risk of hypothyroidism [306]. Several 
studies have shown that regular evaluation of thyroid function is 
needed for a period of at least 10 years after receiving treatment 
for oral cancer. Thyroid dysfunction is a common complication 
in up to 25% of patients with radiation therapy in the head and 
neck area, and this condition is not easily recognized [306,307]. 
Therefore, regular thyroid function tests are recommended in 
patients with oral cancer, especially in those treated with radia-
tion therapy. For patients treated with radiation therapy in the 
head and neck area, the recommended follow-up protocol 
should include an assessment of thyroid function. 
E.  Rehabilitation 
What are the appropriate rehabilitation and supportive ther-
apy options after anticancer treatment?
E1. Speech therapy and swallowing rehabilitation 
Recommendation 30
(A)  Swallowing evaluation and rehabilitation should be of-
fered to all patients with locally advanced oral cancer 
treated with postoperative concurrent chemoradiation 
therapy, within 3 months posttreatment (strong recom-
mendation, moderate-quality evidence).
(B)  Speech evaluation and rehabilitation should be consid-
ered for all patients and oral cancer survivors within 3 
months posttreatment (strong recommendation, moder-
ate-quality evidence).
Chronic dysphagia is more prevalent after multimodality treat-
ment for advanced disease than after low dose/small field irradi-
ation or a single modality treatment. Even with advancements 
in medicine, surgical techniques, and technologies such as inten-
sity-modulated radiation therapy or transoral robotic surgery, 
about half of the patients treated with multimodal therapy for 
locally advanced disease suffer chronic dysphagia [308]. Psycho-
social factors including depression, cognitive dysfunction, defi-
ciency of caregiver support, and sensory changes, may also re-
late to poor oral intake in oral cancer survivors. 
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Although many clinicians believe that swallowing rehabilita-
tion favorably affects not only posttreatment function but also 
quality of life and overall treatment outcome, there are few ran-
domized prospective studies of oral cancer survivors [309]. 
However, increasing data support the finding that swallowing 
evaluation and rehabilitation should be recommended to pa-
tients with locally advanced oral cancer undergoing concurrent 
chemoradiation therapy [309]. While it is difficult to recover 
from persistent dysphagia, patients can benefit from swallowing 
therapy (compensations, exercise, biofeedback) [310-313].
The optimal timing of swallowing rehabilitation has not been 
established. However, limited data suggest that early interven-
tion is more advantageous than delayed intervention [309]. Fur-
thermore, increasing evidence suggests that a “window of op-
portunity” may exist, and may be associated with fibrosis. A 
study reported that the greatest increase in swallowing dysfunc-
tion was noted at three months after treatment, without obvious 
improvement in many of the observed disorders by the end of 
the study [314]. Furthermore, a few retrospective cross-sectional 
or small prospective studies have suggested that pretreatment 
swallowing exercises had favorable effects on posttreatment 
swallowing function.
Voice and speech therapies and related rehabilitation using a 
prosthesis should also be considered. According to two RCTs 
and various non-RCT-based studies, oral cancer survivors should 
be referred to a speech-language therapist for assessment and 
management of voice, speech, and disturbance in resonance 
[315,316]. Early evaluation and treatment are preferred. Use of 
a prosthesis is supported by numerous non-RCT-based studies 
[317]. For instance, obturators fabricated by prosthodontists can 
help speech resonance in patients with oral and oropharyngeal 
defects, and palatal drop prostheses can help proper articulation 
after radical resection of oral cavity structures such as after sub-
total or total glossectomy [318].
E2. Shoulder rehabilitation
Recommendation 31
Shoulder function should be assessed as part of a regular 
follow-up in patients who underwent ND and/or postopera-
tive radiation therapy; early rehabilitation should be consid-
ered where shoulder morbidity exists (strong recommenda-
tion, high-quality evidence).
Shoulder dysfunction and pain are present in almost 70% of pa-
tients who undergo lymph node dissection of the lateral neck. The 
primary cause of shoulder problems is damage to the spinal ac-
cessory nerve (SAN) due to surgical procedures. Radiation ther-
apy can also cause injury to the SAN and other neuromuscular 
structures related to shoulder movement. All the above factors 
may induce rotator cuff tendonitis, adhesive capsulitis, myofas-
cial pain, and other similar conditions. The onset of clinical symp-
toms may take months or even years; therefore caregivers should 
assess shoulder function after treatment by not only directed his-
tory-taking but also by physical examination to periodically eval-
uate patients for shoulder pain or functional impairment.
Oral cancer survivors with shoulder dysfunction and pain 
should be referred for shoulder rehabilitation. A small RCT has 
reported that progressive resistance training (PRT) was better 
than standard physical therapy for oral cancer patients with 
SAN-related shoulder dysfunction [319]. Oral cancer survivors 
with shoulder dysfunction who underwent a PRT program re-
ported obvious reduction in pain and disability in addition to 
improvement of upper extremity strength and endurance [320]. 
A Cochrane review also reported that PRT was more effective 
than standard physical therapy for shoulder dysfunction in pa-
tients treated for head and neck cancer; while PRT improved 
pain, disability, and ROM of shoulder joint, the effect on quality 
of life of head and neck cancer survivors was unclear [319-322].
E3. Lifestyle modification
Recommendation 32
(A)  Regular physical activity (at least 150 minutes of moder-
ate or 75 minutes of vigorous aerobic exercise per week, 
include strength training exercise at least 2 days per 
week should be targeted) is recommended for oral can-
cer survivors (strong recommendation, high-quality evi-
dence). 
(B)  Patients and survivors should avoid alcohol/tobacco 
product consumption (strong recommendation, high-
quality evidence).
(C)  Patients and survivors are encouraged eat a healthy diet 
high in vegetables, fruits, and whole grains, low in satu-
rated fats, and with adequate dietary fiber (strong recom-
mendation, lower-quality evidence).
(D)  Regular dental care, early interventions for oral/dental 
complications, and fastidious oral hygiene are important 
for oral cancer survivors (strong recommendation, low-
quality evidence).
Oral cancer survivors should be advised avoid inactivity and to 
return to normal daily activities as soon as possible after treat-
ment [323,324]. Additionally, as recommended for the general 
population by the American Cancer Society, head and neck can-
cer survivors should try to exercise for at least 150 minutes mod-
erately or 75 minutes vigorously a week and the reinforcement 
exercise should include at least 2 days a week [323]. Preliminary 
evidence with head and neck cancer survivors [325] suggests 
that an individual-tailored exercise regimen can increase func-
tional capacity and quality of life (QoL) of head and neck can-
cer survivors undergoing concurrent chemoradiation therapy 
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[326]. Although evidence is inadequate, generally, performing 
any exercise is better than not exercising, and there is consensus 
about the value of specific exercises appropriate for this patient 
population [327]. If specific impairments are identified such as 
shoulder dysfunction and cervical radiculopathy, oral cancer sur-
vivors should be referred to a rehabilitation specialist [327].
According to rigorous evidence, more than 75% of head and 
neck cancers are related to tobacco and alcohol abuse [328]. 
Thus, in addition to encouraging healthful eating, it is critical to 
emphasize abstinence from tobacco and alcohol consumption. A 
prospective study reported that consuming more than three 
drinks per day was associated with an increased risk of head 
and neck cancer in both men (hazard ratio, 1.48) and women 
(hazard ratio, 2.52) [329]. Alcohol was identified in the 1980s as 
a carcinogen of the upper digestive tract including the oral cavi-
ty, pharynx, and larynx [330], and numerous studies have con-
firmed this finding [331]. It has been noted that compared to 
non-drinkers, alcohol-drinkers who consume about 50 g of alco-
hol per day (more than three drinks) have a 2–3 fold higher risk 
of upper digestive tract cancers. Furthermore, a synergistic effect 
of alcohol consumption and smoking has been implicated in 
head and neck cancer carcinogenesis [332]. 
Oral cancer patients who continued to consume alcohol to-
bacco after diagnosis have been reported to have poorer surviv-
al rates compared to those who abstained [333]. Furthermore, 
even in HPV-related head and neck cancer, the overall prognosis 
was worse among current or the former smokers; current and 
former smokers also showed an increased rate of recurrence 
compared with HPV-related survivors who never smoked [334]. 
Increasing evidence suggests that about 48% of oral cavity [335] 
and pharynx cancer deaths [336] are caused by smoking. Most 
head and neck cancer patients try to quit smoking before or 
during treatment [337], 14%–60% will relapse [338-340]. Con-
tinued smoking is associated with the following negative out-
comes: (1) risk of smoking-associated diseases other than can-
cers (e.g., coronary artery disease); (2) higher rates of second 
primary cancers and recurrence of the original primary cancer 
[341-343]; (3) reduced treatment efficacy [344,345], worsened 
treatment side effects [346,347]; (4) subsequent negative im-
pacts on QoL, morbidity, and mortality [341,348]. Because of 
the numerous benefits of quitting smoking, clinicians should 
strongly encourage and support patients to stop smoking and 
maintain their abstinence. 
Fastidious dental hygiene practices and regularly scheduled 
dental visits are important for oral cancer survivors, and espe-
cially for those received radiation therapy with or without che-
motherapy [349,350]. Oral complications may be influenced by 
several factors. One of the most controllable factors is dental 
and oral hygiene prior to treatment initiation. Commodities that 
can potentially increase the severity of oral side effects should 
consider malnutrition, diabetes, alcohol and tobacco abuse, and 
poor general hygiene. 
The following issues should be assessed during evaluation of 
oral complications: dental caries, gingival status, periodontal ab-
normalities, oral mucosal health, taste perception, production of 
saliva, pain, and swallowing. Long-term oral side effects by 
treatment include neurosensory dysfunction, loss of saliva and 
taste, and other functional changes [350]. If the patient is totally 
or partially edentulous and wears dentures, proper and regular 
fitting should always be recommended [350]. Many oral cancer 
survivors with edentulous areas will experience a remodeling of 
the supportive ridge for the appliance, causing the denture to 
become loose and ill-fitting; the denture may rub the gums, 
tongue, or oral mucosa to the point of ulceration. The device 
must be removed overnight to rest the oral tissue and prevent 
nocturnal bruxing. The dentures should be kept moist while out 
of the patient’s mouth [350]. 
In addition, patients should be advised to avoid mouth-breath-
ing and nasal respiration should be recommended. Mouth-breath-
ing can lead to xerostomia, recurrent oral mucositis, oral infec-
tions, and cause desiccation of the teeth and rapid advancement 
of dental caries [350]. Patients who use a continuous positive 
airway pressure to treat sleep apnea should know that careful 
dental and oral health is most important to avoid caries; caries 
and associated abscesses may increase risks of osteoradionecro-
sis [350].
E4. Psychiatric support 
Recommendation 33
Patients and survivors should be assessed for distress, depres-
sion, and anxiety periodically (3 months posttreatment and 
at least annually) using a validated assessment tool. Counsel-
ing and/or pharmacotherapy should be offered (strong rec-
ommendation, high-quality evidence).
Many cancer survivors have difficulties in returning to “regular 
life” after treatment [351,352]. Many head and neck cancer sur-
vivors have fear of recurrence [353], which impacts mental 
Table 7. General psychosocial long-term and late effects
Depression, depressive symptoms   
Distress—multifactorial unpleasant experience of psychological, social, 
and/or spiritual nature  
Worry, anxiety   
Fear of recurrence   
Pain-related concerns   
End-of-life concerns: death and dying   
Changes in sexual function and/or desire   
Challenges with body image (secondary to surgery, laryngectomy, radiation) 
Challenges with self-image   
Relationship and other social role difficulties   
   Return to work concerns and financial challenges
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health. Additionally, such patients have an increased risk of de-
pression and anxiety [354,355]. Although the estimated preva-
lence of mental problems in cancer survivors is variable, among 
cancer survivors in general, the estimated prevalence of anxiety 
and depression is 17.9% and 11.6%, respectively [356].
Distress for head and neck cancer patients includes worry, 
anxiety, sadness, emotional concerns [357], social disruption 
[358], fear of recurrence, and posttraumatic distress disorder 
(Table 7) [353,359]. One study reported that the incidence of 
depressive disorders was 15% to 50% in head and neck cancer 
patients, in contrast to 15% to 25% in cancer patients in general 
[360]. An analysis of 89 head and neck cancer patients revealed 
that 75% of head and neck cancer patients reported emotional 
concerns and over 50% acknowledged feelings of worry [357]. 
In a larger cohort study, the most common psychological distress 
factors included interpersonal relationships, uncertainty, and in-
terference in activities [361]. 
It is important to monitor the psychological health of the sur-
vivors, caregivers, and the survivor’s family members. The survi-
vor’s financial status, family responsibilities, and access to sup-
port impact the posttreatment psychological status. To provide 
timely and appropriate support for patients, clinicians should be 
familiar with the mental health problems commonly incident af-
ter cancer treatment, the tools to screen for and assess these 
problems, and the resources to provide care (Table 8). A recent 
American Society of Clinical Oncology guideline provides com-
prehensive description of the screening, assessment, and man-
agement of anxiety and depressive symptoms in patients with 
cancer [362].
F. Salvage surgery 
F1. What is role of salvage surgery in the recurrent oral cavity 
cancer?
Recommendation 34
(A)  Salvage surgery should be considered for recurrent oral 
cavity cancer, if resection is feasible (strong recommen-
dation, moderate-quality evidence).
(B)  END can be considered for T2–4 recurrent oral cavity 
cancer (weak recommendation, low-quality evidence).
(B)  END can be considered for T2–4 recurrent oral cavity 
cancer (weak recommendation, low-quality evidence).
(C)  Comprehensive ND should be considered for rN+ recur-
rent oral cavity cancer (strong recommendation, low-
quality evidence).
Overall recurrence rate from a meta-analysis of 1,692 oral cavi-
ty cancer patients was 26%, with a mean local recurrence rate 
of 47.3%, regional recurrence rate of 35.1%, and locoregional 
recurrence rate of 10.9%; the 5-year OS after salvage surgery 
was 37.5%–42.9% [363]. Patients treated with salvage surgery 
showed better survival than did those treated with chemothera-
py and/or RT [364]. Patients with previous treatment to the 
neck presented a poorer survival after recurrence than did those 
without previous treatment [365]. Patients with early clinical 
stage such as a small tumor size (less than 4 cm), or a tumor 
without evidence of bone invasion showed better survival than 
did those with late clinical stage [366]. Patients with late relapse 
or with a disease free-interval of more than 1 year showed sig-
nificantly better survival than did those with early recurrence or 
a disease-free period of less than 1 year [367]. Patients treated 
with surgery alone showed better survival than did those treated 
with surgery followed by RT or with RT alone [368,369]. Extra-
capsular spread was reported as an important prognostic factor 
for salvage surgery [364,366].
Overall complications from salvage surgery have been report-
ed in 37%–60.7% of cases, which is higher compared to that 
from primary surgery. Commonly reported complications in-
clude wound infection, orocutaneous fistula, and wound dehis-
cence and/or flap necrosis [366,368]. Even with free flap recon-
struction, permanent gastrotomy may be required in 25%–50% 
of the patients [366,370]. Therefore, morbidity should be con-
sidered before salvage surgery is to be performed, especially in 
advanced recurrences.
Among patients with oral cavity cancer with negative neck 
who are treated with RT or CRT initially, some show local re-
currence without obvious neck recurrence. Currently, there is 
no clear consensus on the optimal treatment for a node-negative 
neck during the salvage surgery of locally recurrent oral cavity 
cancer. Generally, the risk of occult neck nodal metastasis in a 
Table 8. Validated tools to assess for distress/depression/anxiety
Tool Intended use How it works
Beck Anxiety Inventory (BAI) Screen for anxiety 21 Items, 0 (not problematic)–3 (problematic)
Center for Epidemiological Studies Depression Scale 
(CES-D)
Screen for depression 0–3 Scoring (≥16 suggests clinical depression)
Generalized Anxiety Disorder (GAD)-7 Screen for anxiety 0–3 Scoring for 7 items (≥15 suggests severe anxiety)
Hospital Anxiety and Depression Scale (HADS) Screen for depression and anxiety 0–3 Scoring for 14 items (≥9 suggests clinical significance)
NCCN Distress Thermometer Screen for distress 0 (No distress)–10 (extreme distress), ≥14 suggests clinical 
significance)
Patient Health Questionnaire (PHQ)-9 Screen for depression 0–3 Scoring for 9 items (≥20 suggests severe depression)
NCCN, National Comprehensive Cancer Network.
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clinically N0 oral cavity cancer depends on (1) the primary can-
cer site and (2) T stage classification [371]. END is generally rec-
ommended after evaluation of the characteristics of the primary 
tumor. The likelihood of occult metastasis may be over 20%, 
depending on tumor characteristics such as T stage, site of the 
primary tumor, tumor thickness, etc. [206,372]. In oral cavity 
cancer, it is accepted that a tumor with a DOI of over 4 mm or 
with advanced T stage has over a 20% risk of occult neck me-
tastasis [372,373]. In these cases, END in combination with re-
section of the locally recurred primary tumor has shown prom-
ising results [206,209,372-375]. However, there is no consensus 
regarding management of the N0 neck in patients with locally 
recurrent head and neck cancers. Some authors suggest END 
with the removal of the recurrent primary tumor based on the 
following assumptions: (1) biologic behavior of the recurrent tu-
mor implies a higher risk of lymph node metastasis, and (2) 
there may be residual microscopic tumor in the neck after initial 
RT or CRT. In addition, complex (free flap) reconstruction may 
be necessary after resection of a local recurrence with advanced 
T stage, making neck exposure mandatory for finding and dis-
secting the vessels. Finally, the success rate of a second salvage 
surgery in the neck after a regional recurrence is poor [376-
378]. Some authors suggest a “wait and see” policy, since there 
is a risk of injuring the nerves and vessels, and there is lack of 
evidence to suggest that ND is superior with reference to long-
term prognosis and regional recurrence [379,380]. 
Yirmibesoglu et al. [380] analyzed 44 patients with locally re-
current HNSCC; the patients were originally classified as N0, 
and were initially treated with RT or CRT prior to disease recur-
rence. Of the 44 patients, 30 received END, depending on the 
surgeon’s preference. Positive nodes were found in 10% of the 
patients (3/30). However, the survival rate between ND and ob-
servation groups showed no difference. Solares et al. [381] re-
viewed 69 patients initially treated with RT or CRT, and who 
later developed local recurrence and received salvage surgery 
and ND. Multiple primary sites were as follows: larynx, 37/69 
(53%); oropharynx, 15/69 (22%); hypopharynx, 7/69 (10%); 
and oral cavity, 10/69 (15%). While 17 of 69 patients (24%) 
had nodal metastasis, 7 of 17 (41%) showed more than two 
positive nodes, and 3 of 17 (17%) showed extracapsular inva-
sion. Regarding the frequency of metastasis, supraglottic cancers 
had the highest frequency (55%), followed by hypopharynx 
(43%), oral/oropharynx (20%), and glottis (12%) cancers. Sec-
ond recurrence was observed in 28 of 69 patients (40%). There 
were no neck recurrences when the primary site was controlled. 
Lee et al. [382] analyzed 149 patients with oral cavity, orophar-
ynx, larynx, and hypopharynx cancers who later showed isolat-
ed local recurrence with an N0 neck, and were submitted to sal-
vage surgery. Data showed that 50 of 149 patients (33%) had 
laryngeal cancers (of them, 35 of 50 [70%] showed glottic can-
cer), 47 of 149 (31%) had oral cavity cancers (of them, 27 of 47 
[57%] showed tongue cancer), 23 of 149 (15%) had oropharyn-
geal cancers, and 29 of 149 (19%) had hypopharyngeal cancers. 
The observation group showed 74 hemi-necks and the ND 
group showed 80 hemi-necks. Within the ND group, more hemi-
necks were treated with CRT initially (21 vs. 8) than with exclu-
sive RT (5 vs. 18), while showing more advanced recurrences 
(44 vs. 22). Regional recurrence was seen in 19 patients (10 of 
19 [52%] in the observation group, compared to 9 of 19 [47%] 
in the ND group). Occult lymph node metastasis was found in 
six of 80 (7.5%) of the dissected hemi-necks. In a multivariate 
analysis, the authors found a relationship between ND and bet-
ter regional control and cause-specific survival [382]. However, 
these studies did not analyze oral cavity cancer exclusively, and 
due to the small number of patients, it is not feasible to gauge 
the accuracy of the results. Therefore, it is difficult to draw con-
clusions regarding the need for END. However, in locally recur-
rent oral cavity cancer with a clinically N0 Neck, the risk of oc-
cult neck node metastasis is about 7.5%–17%. Most studies 
suggest ND for patients with more advanced primary or recur-
rent tumor stage and a “wait and see” approach for less ad-
vanced cases. END can be considered in patients with advanced 
locally recurrent oral cavity cancer (rT2–4). In the future, diag-
nostic modalities with enhanced accuracy in finding or exclud-
ing occult metastasis will be developed. However, the final deci-
sion rests with the surgeon, while taking into consideration the 
status of the patient.
A few studies have focused exclusively on regional or locore-
gional recurrence in oral cavity cancer. In a study of recurrent 
oral cavity cancer with regional recurrence, Wong et al. [383] re-
ported that patients with ipsilateral recurrence in a previously 
undissected neck had a surgical salvage rate of 56%, with a 
5-year survival of 32%. However, within the previous ND 
group, these figures fell to 32.5% and 18%, respectively. RT or 
chemotherapy showed no successful salvage (0%). Kowalski 
[365] reported that in a series of 513 patients with oral cancer, 
82 patients (16%) had regional recurrence. Only 51 patients 
(62%) were eligible for salvage treatment. Among 82 regional 
recurrences, 44 were ipsilateral, 31 contralateral, and 7 bilateral. 
Only five of 46 patients (10.8%) who had recurrence in an un-
dissected neck survived. Factors with prognostic significance af-
ter salvage ND were (1) previous ND type, (2) previous RT his-
tory, and (3) recurrence within 6 months (these patients showed 
a statistically better survival than did those with recurrence after 
24 months). Sun et al. [384] reported on 233 cases of tongue 
cancer, 45 of which showed regional recurrence (19.3%). The 
salvage rate was at 26%. In univariate analysis, neck relapse had 
a significantly worse prognosis compared to local recurrence. 
Patients who showed recurrence within 6 months had a worse 
prognosis and surgery showed better results as a method of sal-
vage treatment. In study by Gleich et al. [385], all 18 patients 
with initially advanced oral cavity cancer (T3/4) showed region-
al recurrence. While four of them were treated with RT alone 
and showed persisting tumors or recurrence within 6 months, 
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14 received ND, and showed a mean survival time of 31.1 
months. Six of the ND patients had a prolonged survival dura-
tion. Ord et al. [386] reported on a series of 354 patients with 
oral cancer, and observed that 30 patients showed regional re-
currences (8.5%). They reported that in previous studies, the 
highest success rate of salvage in previously untreated necks was 
63.3% (19/30). The success rate dropped in patients with previ-
ous surgery or RT to the neck. All patients received surgery as a 
mode of salvage treatment, and modified radical ND plus RT 
showed best results. Koo et al. [370] emphasized that in patients 
with recurrent neck disease, aggressive treatment with surgery 
and adjuvant therapy was very important. They concluded that 
surgery was superior to chemotherapy with or without radiation 
therapy at controlling the disease. These studies suggest that the 
prognosis of ipsilateral neck recurrence is better than that of bi-
lateral neck recurrence, and that radical ND improves the sur-
vival rate in patients with regional recurrence in a previous un-
dissected neck. In addition, Jones et al. [376] reviewed 699 head 
and neck cancer patients with primary radical ND. Most of the 
patients receiving primary radical ND suffered no recurrence in 
the neck, and the study reported a cure rate of 56%. Those with 
a recurrence received a second ND, with a cure rate of 31%. 
Those who had no curative treatment to the neck showed a me-
dian survival time of 7 months, with no long-term survivors. 
Based on the results of several studies, comprehensive ND 
should be considered for recurrent oral cavity cancer with re-
gional recurrence. While regional recurrence is one of most im-
portant prognostic factors in oral cavity cancer, the optimal 
management of recurrent lymph node metastasis is worthy of 
more study.
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